USRE38506E1 - Potent inducers of terminal differentiation and methods of use thereof - Google Patents
Potent inducers of terminal differentiation and methods of use thereof Download PDFInfo
- Publication number
- USRE38506E1 USRE38506E1 US10/004,411 US441101A USRE38506E US RE38506 E1 USRE38506 E1 US RE38506E1 US 441101 A US441101 A US 441101A US RE38506 E USRE38506 E US RE38506E
- Authority
- US
- United States
- Prior art keywords
- group
- compound
- hydrogen atom
- hydroxyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 0 [1*]C(=O)CC([2*])=O Chemical compound [1*]C(=O)CC([2*])=O 0.000 description 46
- CJNDVJIYUGLRMO-UHFFFAOYSA-N [H]N(C(=O)CC(=O)NO)C1=CC=CC=C1 Chemical compound [H]N(C(=O)CC(=O)NO)C1=CC=CC=C1 CJNDVJIYUGLRMO-UHFFFAOYSA-N 0.000 description 3
- UYWMXHFOTLWYES-UHFFFAOYSA-N CC(=O)C(C)CC(C)C(=O)[Y] Chemical compound CC(=O)C(C)CC(C)C(=O)[Y] UYWMXHFOTLWYES-UHFFFAOYSA-N 0.000 description 2
- YEFGEWYFRIYMTG-UHFFFAOYSA-N CN(C)C(=O)CCCCCCC(=O)NO Chemical compound CN(C)C(=O)CCCCCCC(=O)NO YEFGEWYFRIYMTG-UHFFFAOYSA-N 0.000 description 2
- AZXFTGCULLLSAO-UHFFFAOYSA-N CONC(=O)CCCCCCC(=O)NO Chemical compound CONC(=O)CCCCCCC(=O)NO AZXFTGCULLLSAO-UHFFFAOYSA-N 0.000 description 2
- WHJGNZKHQCAENL-UHFFFAOYSA-N N#CCCCCCC(=O)NO Chemical compound N#CCCCCCC(=O)NO WHJGNZKHQCAENL-UHFFFAOYSA-N 0.000 description 2
- HPYIQEPMFZRGTE-UHFFFAOYSA-N O=C(CCCCCCC(=O)N1CCCCC1)NO Chemical compound O=C(CCCCCCC(=O)N1CCCCC1)NO HPYIQEPMFZRGTE-UHFFFAOYSA-N 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=CC=CC=C1)NO Chemical compound O=C(CCCCCCC(=O)NC1=CC=CC=C1)NO WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- ATGOFQDKNRCCKN-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1CCCCC1)NO Chemical compound O=C(CCCCCCC(=O)NC1CCCCC1)NO ATGOFQDKNRCCKN-UHFFFAOYSA-N 0.000 description 2
- OWDYDLVCUCFVDV-UHFFFAOYSA-N O=C(CCCCCCC(=O)NCC1=CC=CC=C1)NO Chemical compound O=C(CCCCCCC(=O)NCC1=CC=CC=C1)NO OWDYDLVCUCFVDV-UHFFFAOYSA-N 0.000 description 2
- HCPFWRDPFXZWGW-UHFFFAOYSA-N O=C(NO)C1=CC=C(C(=O)NC2=CC=CC=C2)C=C1 Chemical compound O=C(NO)C1=CC=C(C(=O)NC2=CC=CC=C2)C=C1 HCPFWRDPFXZWGW-UHFFFAOYSA-N 0.000 description 2
- WPRUZFZLNBUKRM-UHFFFAOYSA-N O=C(O)CCCCCCC(=O)NC1=CC=C([N+](=O)[O-])C=C1 Chemical compound O=C(O)CCCCCCC(=O)NC1=CC=C([N+](=O)[O-])C=C1 WPRUZFZLNBUKRM-UHFFFAOYSA-N 0.000 description 2
- PEQFCLWWWFUEEK-UHFFFAOYSA-N O=C(O)CCCCCCC(=O)NC1CCCCC1 Chemical compound O=C(O)CCCCCCC(=O)NC1CCCCC1 PEQFCLWWWFUEEK-UHFFFAOYSA-N 0.000 description 2
- YNBDVONJRSJFLP-UHFFFAOYSA-N O=C(O)CCCCCCC(=O)NO Chemical compound O=C(O)CCCCCCC(=O)NO YNBDVONJRSJFLP-UHFFFAOYSA-N 0.000 description 2
- JEFYNJITVXDXNQ-UHFFFAOYSA-N [C-]#[N+]C1=CC=C(NC(=O)CCCCCCC(=O)O)C=C1 Chemical compound [C-]#[N+]C1=CC=C(NC(=O)CCCCCCC(=O)O)C=C1 JEFYNJITVXDXNQ-UHFFFAOYSA-N 0.000 description 2
- NERQMQQOJNXZSF-UHFFFAOYSA-N C.C.C.C.CC(=O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)[Y])C=C1 Chemical compound C.C.C.C.CC(=O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)[Y])C=C1 NERQMQQOJNXZSF-UHFFFAOYSA-N 0.000 description 1
- SHVZYKRUQVFDCX-UHFFFAOYSA-N C.C.CC(=O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)[Y])C=C1 Chemical compound C.C.CC(=O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)[Y])C=C1 SHVZYKRUQVFDCX-UHFFFAOYSA-N 0.000 description 1
- FHIWHQBWKCZLQJ-UHFFFAOYSA-N C.C.N=C(O)OC1=CC=C(NC(=O)CC(=O)NC2=CC=C(C(=O)NO)C=C2)C=C1 Chemical compound C.C.N=C(O)OC1=CC=C(NC(=O)CC(=O)NC2=CC=C(C(=O)NO)C=C2)C=C1 FHIWHQBWKCZLQJ-UHFFFAOYSA-N 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N CC(=O)NO Chemical compound CC(=O)NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- VLSZLHSPNVETRL-UHFFFAOYSA-N CC(C)(C)ONC(=O)CCCCCCC(=O)NO Chemical compound CC(C)(C)ONC(=O)CCCCCCC(=O)NO VLSZLHSPNVETRL-UHFFFAOYSA-N 0.000 description 1
- SAOZUDQYEZQBIT-UHFFFAOYSA-N CC(CCC(=O)NO)CCC(=O)NO Chemical compound CC(CCC(=O)NO)CCC(=O)NO SAOZUDQYEZQBIT-UHFFFAOYSA-N 0.000 description 1
- YFMKFIIHENDHSR-UHFFFAOYSA-N CC(CCCCC(C)C(=O)N(C)C)C(=O)N(C)C Chemical compound CC(CCCCC(C)C(=O)N(C)C)C(=O)N(C)C YFMKFIIHENDHSR-UHFFFAOYSA-N 0.000 description 1
- DAFGPQQKCZGAIN-UHFFFAOYSA-N CC(CCCCCC(C)C(=O)N(C)C)C(=O)N(C)C Chemical compound CC(CCCCCC(C)C(=O)N(C)C)C(=O)N(C)C DAFGPQQKCZGAIN-UHFFFAOYSA-N 0.000 description 1
- MCUFFAPLDKFWCI-UHFFFAOYSA-N CN(C(=O)CCCCCCC(=O)NO)C1=CC=CC=C1 Chemical compound CN(C(=O)CCCCCCC(=O)NO)C1=CC=CC=C1 MCUFFAPLDKFWCI-UHFFFAOYSA-N 0.000 description 1
- IPKIFKKWSYGWOO-UHFFFAOYSA-N CN(C)C(=O)CC(=O)N(C)C1=CC=CC=C1 Chemical compound CN(C)C(=O)CC(=O)N(C)C1=CC=CC=C1 IPKIFKKWSYGWOO-UHFFFAOYSA-N 0.000 description 1
- ZPBIPEKGLGVMMY-UHFFFAOYSA-N CN(CCN(C)C(=O)CCCCCCC(=O)O)C(=O)CCCCCCC(=O)O Chemical compound CN(CCN(C)C(=O)CCCCCCC(=O)O)C(=O)CCCCCCC(=O)O ZPBIPEKGLGVMMY-UHFFFAOYSA-N 0.000 description 1
- CITZADBTCJYGCM-UHFFFAOYSA-N CN(CN(C)C(=O)CC(=O)O)C(=O)CC(=O)O Chemical compound CN(CN(C)C(=O)CC(=O)O)C(=O)CC(=O)O CITZADBTCJYGCM-UHFFFAOYSA-N 0.000 description 1
- OXFDJRPOLHXFJT-UHFFFAOYSA-N CNC(=O)C1=CC=C(NC(=O)CCCCCCC(=O)NC2=CC=C(C(=O)NC)C=C2)C=C1 Chemical compound CNC(=O)C1=CC=C(NC(=O)CCCCCCC(=O)NC2=CC=C(C(=O)NC)C=C2)C=C1 OXFDJRPOLHXFJT-UHFFFAOYSA-N 0.000 description 1
- MPCJIGILBNVNJM-UHFFFAOYSA-N COC(=O)CCCCCCC(=O)/N=O\CC1=CC=CC=C1 Chemical compound COC(=O)CCCCCCC(=O)/N=O\CC1=CC=CC=C1 MPCJIGILBNVNJM-UHFFFAOYSA-N 0.000 description 1
- WMMXJCQWLLQMBW-UHFFFAOYSA-N COC(=O)CCCCCCC(=O)NO Chemical compound COC(=O)CCCCCCC(=O)NO WMMXJCQWLLQMBW-UHFFFAOYSA-N 0.000 description 1
- ICTBAXSJZJMYRC-UHFFFAOYSA-N N#CC1=CC=CC=C1NC(=O)CCCCCCC(=O)NO Chemical compound N#CC1=CC=CC=C1NC(=O)CCCCCCC(=O)NO ICTBAXSJZJMYRC-UHFFFAOYSA-N 0.000 description 1
- MZFZLFNKCVOXHV-UHFFFAOYSA-N N#CCC1=CC=C(NC(=O)CCCCCCC(=O)NC2=CC=C(CC#N)C=C2)C=C1 Chemical compound N#CCC1=CC=C(NC(=O)CCCCCCC(=O)NC2=CC=C(CC#N)C=C2)C=C1 MZFZLFNKCVOXHV-UHFFFAOYSA-N 0.000 description 1
- ZQWLCPWAAFPWKG-UHFFFAOYSA-N NC1=C2N=CC(NC(=O)CCCCCCC(=O)N3C=NC4=C(N)N=CN=C43)C2=NC=N1.O=C(CCCCCCC(=O)N1CCCCC1)N1CCCCC1.O=C(CCCCCCC(=O)NC1=CN=CC=C1)NC1=CN=CC=C1.O=C(CCCCCCC(=O)NC1CCCCC1)NC1CCCCC1 Chemical compound NC1=C2N=CC(NC(=O)CCCCCCC(=O)N3C=NC4=C(N)N=CN=C43)C2=NC=N1.O=C(CCCCCCC(=O)N1CCCCC1)N1CCCCC1.O=C(CCCCCCC(=O)NC1=CN=CC=C1)NC1=CN=CC=C1.O=C(CCCCCCC(=O)NC1CCCCC1)NC1CCCCC1 ZQWLCPWAAFPWKG-UHFFFAOYSA-N 0.000 description 1
- VPMXQAJURGFJSD-UHFFFAOYSA-N O=C(C=CC1=CC=C(C=CC(=O)NO)C=C1)CNC1=CC=CC=C1 Chemical compound O=C(C=CC1=CC=C(C=CC(=O)NO)C=C1)CNC1=CC=CC=C1 VPMXQAJURGFJSD-UHFFFAOYSA-N 0.000 description 1
- AZFZJJXSLKEWEW-UHFFFAOYSA-N O=C(CC(=O)NC1=NC=CS1)NC1=NC=CS1 Chemical compound O=C(CC(=O)NC1=NC=CS1)NC1=NC=CS1 AZFZJJXSLKEWEW-UHFFFAOYSA-N 0.000 description 1
- IZWSVCCPMFMXTH-UHFFFAOYSA-N O=C(CCC(F)(F)CCC(=O)NO)NO Chemical compound O=C(CCC(F)(F)CCC(=O)NO)NO IZWSVCCPMFMXTH-UHFFFAOYSA-N 0.000 description 1
- XMRUPYQQGJFOTD-UHFFFAOYSA-N O=C(CCCCCC(CCCCCC(=O)NO)C(=O)NO)NO Chemical compound O=C(CCCCCC(CCCCCC(=O)NO)C(=O)NO)NO XMRUPYQQGJFOTD-UHFFFAOYSA-N 0.000 description 1
- GSSGHQQPRUHLKN-UHFFFAOYSA-N O=C(CCCCCCC(=O)N1CCCCC1)NO.O=C(CCCCCCC(=O)NC1CCCCC1)NO Chemical compound O=C(CCCCCCC(=O)N1CCCCC1)NO.O=C(CCCCCCC(=O)NC1CCCCC1)NO GSSGHQQPRUHLKN-UHFFFAOYSA-N 0.000 description 1
- JDXSPPXVFXRJIC-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=CC(F)=CC(F)=C1)NO Chemical compound O=C(CCCCCCC(=O)NC1=CC(F)=CC(F)=C1)NO JDXSPPXVFXRJIC-UHFFFAOYSA-N 0.000 description 1
- BFZOAUGHLFQHFC-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=CC([N+](=O)[O-])=CC=C1)NO Chemical compound O=C(CCCCCCC(=O)NC1=CC([N+](=O)[O-])=CC=C1)NO BFZOAUGHLFQHFC-UHFFFAOYSA-N 0.000 description 1
- JOQMLAXPVCWJEF-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=CC=C(C(=O)NC2=CC=CC=C2)C=C1)NO Chemical compound O=C(CCCCCCC(=O)NC1=CC=C(C(=O)NC2=CC=CC=C2)C=C1)NO JOQMLAXPVCWJEF-UHFFFAOYSA-N 0.000 description 1
- FKCJMXZOFAFKRT-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=CC=C(C(F)(F)F)C=C1)NC1=CC=C(C(F)(F)F)C=C1 Chemical compound O=C(CCCCCCC(=O)NC1=CC=C(C(F)(F)F)C=C1)NC1=CC=C(C(F)(F)F)C=C1 FKCJMXZOFAFKRT-UHFFFAOYSA-N 0.000 description 1
- XMDBXLDSOVGJQR-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=CC=C([N+](=O)[O-])C=C1)NC1=CC=C(C(=O)O)C=C1 Chemical compound O=C(CCCCCCC(=O)NC1=CC=C([N+](=O)[O-])C=C1)NC1=CC=C(C(=O)O)C=C1 XMDBXLDSOVGJQR-UHFFFAOYSA-N 0.000 description 1
- IRWLWXCWGWIZEC-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=CC=CN=C1)NC1=CC=CN=C1 Chemical compound O=C(CCCCCCC(=O)NC1=CC=CN=C1)NC1=CC=CN=C1 IRWLWXCWGWIZEC-UHFFFAOYSA-N 0.000 description 1
- AZGGMUWCWPDNHE-UHFFFAOYSA-N O=C(CCCCCCC(=O)NC1=NC=CS1)NC1=NC=CS1 Chemical compound O=C(CCCCCCC(=O)NC1=NC=CS1)NC1=NC=CS1 AZGGMUWCWPDNHE-UHFFFAOYSA-N 0.000 description 1
- PJPKVZUOPKSZEI-UHFFFAOYSA-N O=C(CCCCCCC(=O)NOCC1=CC=CC=C1)NO Chemical compound O=C(CCCCCCC(=O)NOCC1=CC=CC=C1)NO PJPKVZUOPKSZEI-UHFFFAOYSA-N 0.000 description 1
- SNSQMUAYBBGVBM-UHFFFAOYSA-N O=C(O)CC(=O)N(O)C(=O)CC(=O)O Chemical compound O=C(O)CC(=O)N(O)C(=O)CC(=O)O SNSQMUAYBBGVBM-UHFFFAOYSA-N 0.000 description 1
- SNYBUXDHAFFOTI-UHFFFAOYSA-N O=C(O)CC(=O)N1CCCCC1 Chemical compound O=C(O)CC(=O)N1CCCCC1 SNYBUXDHAFFOTI-UHFFFAOYSA-N 0.000 description 1
- WDCJISLTYYFHIK-UHFFFAOYSA-N O=C(O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)O)C=C1 Chemical compound O=C(O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)O)C=C1 WDCJISLTYYFHIK-UHFFFAOYSA-N 0.000 description 1
- PGMVKOSVBZGIFE-UHFFFAOYSA-N O=C(O)CCCCCC(=O)N(O)C(=O)CCCCCC(=O)O Chemical compound O=C(O)CCCCCC(=O)N(O)C(=O)CCCCCC(=O)O PGMVKOSVBZGIFE-UHFFFAOYSA-N 0.000 description 1
- PAXDAFSGJPGLGR-UHFFFAOYSA-N O=C(O)CCCCCCC(=O)NC1=CC=CC=C1 Chemical compound O=C(O)CCCCCCC(=O)NC1=CC=CC=C1 PAXDAFSGJPGLGR-UHFFFAOYSA-N 0.000 description 1
- OQJMYJRGZHGUNS-UHFFFAOYSA-N O=C(O)CCCCCCC(=O)NC1=CC=NC=C1 Chemical compound O=C(O)CCCCCCC(=O)NC1=CC=NC=C1 OQJMYJRGZHGUNS-UHFFFAOYSA-N 0.000 description 1
- CKWMYSIKTQTPNP-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(NC(=O)CCCCCCC(=O)NO)=C1 Chemical compound [C-]#[N+]C1=CC=CC(NC(=O)CCCCCCC(=O)NO)=C1 CKWMYSIKTQTPNP-UHFFFAOYSA-N 0.000 description 1
- BZEIKXJFTSOWBM-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(NC(=O)CCCCCCC(=O)O)=C1 Chemical compound [C-]#[N+]C1=CC=CC(NC(=O)CCCCCCC(=O)O)=C1 BZEIKXJFTSOWBM-UHFFFAOYSA-N 0.000 description 1
- SOLZOGDEOLHQOK-UHFFFAOYSA-N [H]N(C(=O)CC(=O)N(C)C)C1=CC=CC=C1 Chemical compound [H]N(C(=O)CC(=O)N(C)C)C1=CC=CC=C1 SOLZOGDEOLHQOK-UHFFFAOYSA-N 0.000 description 1
- VOXPFQFSRHZUBY-UHFFFAOYSA-N [H]N(C(=O)CC(=O)O)C1=CC=CC=N1 Chemical compound [H]N(C(=O)CC(=O)O)C1=CC=CC=N1 VOXPFQFSRHZUBY-UHFFFAOYSA-N 0.000 description 1
- RYGZYXMNALDTAQ-UHFFFAOYSA-N [H]N(C(=O)CC(=O)O)C1=CC=CN=C1 Chemical compound [H]N(C(=O)CC(=O)O)C1=CC=CN=C1 RYGZYXMNALDTAQ-UHFFFAOYSA-N 0.000 description 1
- ZTRAGQCZSHCMBF-UHFFFAOYSA-N [H]N(C(=O)CC(=O)O)C1=CC=NC=C1 Chemical compound [H]N(C(=O)CC(=O)O)C1=CC=NC=C1 ZTRAGQCZSHCMBF-UHFFFAOYSA-N 0.000 description 1
- LUKAPVXTMOBHFZ-UHFFFAOYSA-N [H]N(C(=O)CC(=O)O)C1CCCCC1 Chemical compound [H]N(C(=O)CC(=O)O)C1CCCCC1 LUKAPVXTMOBHFZ-UHFFFAOYSA-N 0.000 description 1
- SWHPYSFPZBPPLY-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)NC)C1=CC=CC=C1 Chemical compound [H]N(C(=O)CCCCCCC(=O)NC)C1=CC=CC=C1 SWHPYSFPZBPPLY-UHFFFAOYSA-N 0.000 description 1
- IEONUTSGFSLIPV-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)O)C1=CC=C(OCC2=CC=CC=C2)C=C1 Chemical compound [H]N(C(=O)CCCCCCC(=O)O)C1=CC=C(OCC2=CC=CC=C2)C=C1 IEONUTSGFSLIPV-UHFFFAOYSA-N 0.000 description 1
- GFEJXTUJFDKNBH-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)O)C1=CC=CC(C#N)=C1 Chemical compound [H]N(C(=O)CCCCCCC(=O)O)C1=CC=CC(C#N)=C1 GFEJXTUJFDKNBH-UHFFFAOYSA-N 0.000 description 1
- PQABOQDDEDACEL-UHFFFAOYSA-N [H]N(CC1=CC=CC=C1)C(=O)CCCCCCC(=O)NC Chemical compound [H]N(CC1=CC=CC=C1)C(=O)CCCCCCC(=O)NC PQABOQDDEDACEL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which normally govern proliferation and differentiation.
- chemotherapeutic treatment of cancer a) blocking hormone-dependent tumor cell proliferation by interference with the production of peripheral action of sex hormones; and b) killing cancer cells directly by exposing them to cytotoxic substances, which injure both neoplastic and normal cell populations.
- cancer therapy is also being attempted by the induction of terminal differentiation of the neoplastic cells (1).
- differentiation has been reported by exposure of cells to a variety of stimuli, including: cyclic AMP and retinoic acid (2,3), aclarubicin and other anthracyclines (4).
- neoplastic transformation does not necessarily destroy the potential of cancer cells to differentiate (1,5,6).
- tumor cells which do not respond to the normal regulators of proliferation and appear to be blocked in the expression of their differentiation program, and yet can be induced to differentiate and cease replicating.
- agents including some relatively simple polar compounds (5,7-9), derivatives of vitamin D and retinoic acid (10-12), steroid hormones (13), growth factors (6,14), proteases (15,16), tumor promoters (17,18), and inhibitors of DNA or RNA synthesis (4,19-24), can induce various transformed cell lines and primary human tumor explants to express more differentiated characteristics.
- HMBA human erythroleukemia cells
- Commitment is defined as the capacity of cells to express terminal differentiation despite removal of inducer (25). Upon continued exposure to HMBA there is progressive recruitment of cells to differentiate. The present inventors have reported that MELC cell lines made resistant to relatively low levels of vincristine become markedly more sensitive to the inducing action of HMBA and can be induced to differentiate with little or no latent period (26).
- HMBA is capable of inducing phenotypic changes consistent with differentiation in a broad variety of cells lines (5).
- the characteristics of the drug induced effect have been most extensively studied in the murine erythroleukemia cell system (MELC) (5,25,27,28).
- MELC induction of differentiation is both time and concentration dependent.
- the minimum concentration required to demonstrate an effect in vitro in most strains is 2 to 3 mM; the minimum duration of continuous exposure generally required to induce differentiation in a substantial portion (>20%) of the population without continuing drug exposure is about 36 hours.
- HMBA protein kinase C is involved in the pathway of inducer-mediated differentiation (29).
- the in vitro studies provided a basis for evaluating the potential of HMBA as a cytodifferentiation agent in the treatment of human cancers (30).
- phase I clinical trials with HMBA have been completed (31-36). Clinical trials have shown that this compound can induce a therapeutic response in patients with cancer (35,36).
- phase I clinical trials also have demonstrated that the potential efficacy of HMBA is limited, in part, by dose-related toxicity which prevents achieving optimal blood levels and by the need for intravenous administration of large quantities of the agent, over prolonged periods.
- the best compounds comprise two polar end groups separated by a flexible chain of methylene groups, wherein one or both of the polar end groups is a large hydrophobic group.
- the polar end groups are different and only one is a large hydrophobic group.
- This new class of compounds of the present invention may be useful for selectively inducing terminal differentiation of neoplastic cells and therefore aid in treatment of tumors in patients.
- the present invention provides the compound having the structure:
- the present invention also provides the compound above having the structure:
- each of R 3 and R 4 are independently the same as or different from each other are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R 3 and R 4 bond together to form a piperidine group;
- R 2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
- the present invention also provides the compound above having the structure:
- R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; and n is an integer from about 4 to about 8.
- the present invention also provides the compound having the structure:
- each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group;
- R is a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
- the present invention further provides the compound having the structure:
- the present invention still further provides the compound having the structure:
- the present invention also provides the compound having the structure:
- each of X and Y are independently, the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
- the present invention also provides the compound having the structure
- the present invention further provides the compound having the structure:
- each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and n is an integer from about 0 to about 8.
- the present invention still further provides the compound having the structure:
- the present invention also provides the compound having the structure:
- each of R 1 and R 2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
- the present invention also provides the compound having the structure:
- each of R 1 and R 2 are independently the same as or different form each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
- the present invention further provides the compound having the structure:
- each of R 1 and R 2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
- the present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation.
- the present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of any of the compounds above.
- the present invention provides the compound having the structure:
- the present invention also provides the compound above having the structure:
- each of R 3 and R 4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R 3 and R 4 bond together to form a piperidine group;
- R 2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
- R 2 is a hydroxylamino, hydroxyl, amino, methylamino, dimethylamino, or methoxy group and n is 6.
- R 4 is a hydrogen atom and R 3 is a substituted or unsubstituted phenyl group.
- the phenyl group may be substituted with a methyl, cyano, nitro, trifluoromethyl, amino, aminocarbonyl, methylcyano, chloro, fluoro, bromo, iodo, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl, hydroxyl, methyoxy, benzyloxy, phenylaminooxy, phenylmethoxy, phenylaminocarbonyl, methoxycarbonyl, methylaminocarbonyl,
- R 4 is a hydrogen atom and R 3 is a cyclohexyl group; R 4 is a hydrogen atom and R 3 is a methyoxy group; R 3 and R 4 each bond together to form a piperidine group; R 4 is a hydrogen atom and R 3 is a hydroxyl group; R 4 is a hydrogen atom and R 3 is a benzyloxy group; R 4 is a hydrogen atom and R 3 is a ⁇ -pyridine group; R 4 is a hydrogen atom and R 3 is a ⁇ -pyridine group; R 4 is a hydrogen atom and R 3 is a ⁇ -pyridine group; R 4 is a hydrogen atom and R 3 is a ⁇ -pyridine group; R 3 and R 4 are both methyl groups; or R 4 is a methyl group and R 3 is a phenyl group.
- the present invention also provides the compound having the structure:
- R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; and n is an integer from about 4 to about 8.
- R is a substituted or unsubstituted phenylamino group.
- the phenylamino group may be substituted with a cyano, methylcyano, nitro, carboxyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, trifluoromethyl, hydroxylaminocarbonyl, N-hydroxylaminocarbonyl, methoxycarbonyl, chloro, fluoro, methyl, methoxy, 2,3-difluoro, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 2,6-difluoro, 3,5-difluoro, 2,6-difluoro, 2,3,6-trifluoro, 1,2,3-trifluoro, 3,4,5-trifluoro, 2,3,4,5-tetrafluoro, or 2,3,4,5,6-pentafluoro group.
- R is a cyclohexylamino group.
- the present invention also provides the compound having the structure:
- each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group;
- each of X, Y, and R is a hydroxyl group and each of m and n is 5.
- the present invention also provides the compound having the structure:
- each of X and Y is a hydroxyl group and each of R 1 and R 2 is a methyl group.
- each of n and o is 6, and m is 2.
- the present invention also provides the compound having the structure:
- the present invention also provides the compound having the structure:
- each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
- each of X and Y is a hydroxyl group and each of m and n is 5.
- the present invention also provides the compound having the structure:
- the present invention also provides the compound having the structure:
- each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and n is an integer from about 0 to about 8.
- each of X and Y is a dimethylamino group and n is 4 or 5.
- the present invention also provides the compound having the structure:
- each of X and Y is a hydroxylamino group
- R 1 is a methyl group
- R 2 is a hydrogen atom
- each of m and n is 2.
- each of X and Y is a hydroxylamino group
- R 1 is a carbonylhydroxylamino group
- R 2 is a hydrogen atom
- each of m and n is 5.
- each of X and Y is a hydroxylamino group
- each of R 1 and R 2 is a fluoro group
- each of m and n is 2.
- the present invention also provides the compound having the structure:
- each of R 1 and R 2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
- R 1 is a phenylamino group and R 2 is a hydroxylamino group.
- the present invention also provides the compound having the structure:
- each of R 1 and R 2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
- R 1 is phenylamino group and R 2 is hydroxylamino group.
- the present invention also provides the compound having the structure:
- each of R 1 and R 2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
- R 1 or R 2 is a hydroxylamino group.
- the present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation.
- the contacting must be performed continuously for a prolonged period of time, i.e. for at least 48 hours, preferably for about 4-5 days or longer.
- the method may be practiced in vivo or in vitro. If the method is practiced in vitro, contacting may be effected by incubating the cells with the compound.
- the concentration of the compound in contact with the cells should be from about 1 ⁇ M to about 25 mM, preferably from 4 ⁇ M to about 5 mM. The concentration depends upon the individual compound and the state of the neoplastic cells.
- the method may also comprise initially treating the cells with an antitumor agent so as to render them resistant to an antitumor agent and subsequently contacting the resulting resistant cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such cells.
- the antitumor agent may be one of numerous chemotherapy agents such as an alkylating agent, an antimetabolite, a hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, mitotane, nitrosoureas or an imidazole carboxamide. Suitable agents are those agents which promote depolarization of tubulin.
- the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine.
- the cells preferably are treated so that they are resistant to vincristine at a concentration of about 5 mg/ml.
- the treating of the cells to render them resistant to an antitumor agent may be effected by contacting the cells with the agent for a period of at least 3-5 days. The contacting of the resulting cells with any of the compounds above is performed as described previously.
- the present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
- the method of the present invention is intended for the treatment of human patients with tumors. However, it is also likely that the method would be effective in the treatment of tumors in other mammals.
- the term tumor is intended to include any cancer caused by the proliferation of neoplastic cells, such as lung cancer, acute lymphoid myeloma, bladder melanoma, renal carcinoma, breast carcinoma, or colorectal carcinoma.
- the administration of the compound to the patient may be effected orally or parenterally. To date administration intravenously has proven to be effective.
- the administration of the compound must be performed continuously for a prolonged period of time, such as for at least 3 days and preferably more than 5 days.
- the administration is effected continuously for at least 10 days and is repeated at intervals wherein at each interval the administration is continuously effected for at least 10 days.
- the administration may be effected at intervals as short as 5-10 days, up to about 25-35 days and continuously for at least 10 days during each such interval.
- the optimal interval period will vary depending on the type of patient and tumor. For example, in the incidence of acute leukemia, the so called myelodysplastic syndrome, continuous infusion would seem to be indicated so long as the patient tolerated the drug without toxicity and there was a positive response.
- the amount of the compound administered to the patient is less than an amount which would cause toxicity in the patient.
- the amount of the compound which is administered to the patient is less than the amount which causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compound.
- the concentration of the compound in the patient's plasma is maintained at about 1.0 mM. It has been found with HMBA that administration of the compound in an amount from about 5 gm/m 2 /day to about 30 gm/m 2 /day, particularly about 20 gm/m 2 /day, is effective without producing toxicity in the patient.
- the optimal amount of the compound which should be administered to the patient in the practice of the present invention will depend on the particular compound used and the type of cancer being treated.
- homologs are molecules having substantial structural similarities to the above-descried compounds and analogs are molecules having substantial biological similarities regardless of structural similarities.
- the method may also comprise initially administering to the patient an amount of an antitumor agent to render the cells resistant to an antitumor agent and subsequently administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
- the antitumor agent may be one of numerous chemotherapy agents such as an alkylating agent, an antimetabolite, a hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, mitotane, nitrosoureas of an imidazole carboxamide. Suitable agents are those agents which promote depolarization of tubulin.
- the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine.
- an amount is administered to render the cells are resistant to vincristine at a concentration of bout 5 mg/ml.
- the administration of the agent is performed essentially as described above for the administration of any of the compounds.
- the administration of the agent is for a period of at least 3-5 days.
- the administration of any of the compounds above is performed as descried previously.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier, such as sterile pyrogen-free water, and a therapeutically acceptable amount of any of the compounds above.
- the effective amount is an amount effective to selectively induce terminal differentiation of suitable neoplastic cells and less than an amount which causes toxicity in a patient.
- the present invention provides the pharmaceutical composition above in combination with an antitumor agent.
- the antitumor agent may be any of the agents previously described.
- MELC 745A-DS19 cells and the variants of MELC derived from this cell line namely, the vincristine-resistant MELC V3.17 and VCR.C(2)15 cell lines (26), and the dimethylsulfoxide-resistant cell line, DR10 (39), were maintained in alpha minimal essential medium containing 10% fetal calf serum (16).
- Cell cultures for all experiments were initiated with cells in logarithmic growth phase (day 2 cultured cells) at a density of 10 5 cells/ml. Inducer compounds were added in the final concentrations indicated below, dissolved in culture medium without fetal calf serum unless otherwise indicated. Cell density and benzidine reactively were determined as described (16).
- HL-60 human leukemia cells derived from peripheral blood leukocytes of a patient with acute promyelocytic leukemia (40). Induced differentiation of HL-60 cells assayed by determining the proportion of cells that developed the capacity to reduce nitroblue tetrazolium (NBT) (41) (see Table 2 for results).
- Suberic acid monobenzyloxyamide monomethyl ester (1 g; 3.4 mmol) and potassium hydroxide (210 mg; 3.75 mmol) were dissolved in 10 mL of methanol-water (4:1) mixture. The reaction mixture was refluxed two hours and solvent was evaporated. The solid residue was dissolved in 5 mL water and acidified with conc. hydrochloric acid to pH ⁇ 5. White precipitate was filtered, dried and crystallized from ethyl acetate-hexanes. The yield of suberic acid monobenzyloxyamide was 820 mg (86%). The product was dissolved in methanol (50 mL) and 5% Pd-C (50 mg) was added.
- N-benzyloxy-6-bromohexanoyl amide was 4.7 g (78%).
- a dimethylsulfoxide (250 mL) solution of N-benzyloxy-6-bromohexanoyl amide (4.5 g; 15 mmol) and sodium cyanide (7.35 g; 0.15 mol) was heated at 130° C. overnight.
- the solvent was evaporated and solid residue was partitioned between chloroform (300 mL) and water (300 mL).
- the chloroform layer was washed with water (5 ⁇ 100 mL), dried over anhydrous magnesium sulfate, and evaporated.
- the oily residue was purified by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1) as an eluent.
- the yield of N-benzyloxy-6-cyanohexanoylamide was 1.62 g (43%).
- the product was dissolved in methanol (50 mL) and 5% Pd-C (100 mg) was added.
- the black suspension was shaken under hydrogen pressure ( ⁇ 50 psi) overnight.
- the catalyst was isolated by filtration and filtrate was evaporated.
- the solid residue was slurried in hexanes ( ⁇ 20 mL) and filtered.
- the yield of N-hydroxy-6-cyanohexanoylamide was 900 mg (overall yield 30%).
- a diacid dichloride (0.01 mol) was added into a cooled (0° C.) solution of potassium hydroxide (1.12 g: 0.02 mol) and corresponding amine (0.01 mol) in 30 mL of tetrahydrofuran-water (1:1) mixture.
- the reaction mixture was stirred at room temperature about one hour.
- Solvent was evaporated and the solid residue was partitioned between chloroform (300 mL) and water (300 mL). In some cases a small amount of methanol is necessary to dissolve all solid.
- the organic layer was washed with 10% potassium hydroxide (3 ⁇ 30 mL).
- the basic water extract was acidified with 10% hydrochloric acid.
- the precipitate was collected by filtration, dried and purified by crystallization from ethyl acetate or by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1). The yields are from 20-37%.
- N 4, 5, 6, 7, and 8;
- R is hydrogen; 2-, 3-, and 4-cyano; 2-, 3-, and 4-nitro; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-trifluoromethyl; 2-, 3-, and 4-fluoro:
- n 4, 5, 6, 7, and 8:
- n 4, 5, 6, 7, and 8;
- n 4, 5, 6, 7, and 8;
- n 4, 5, 6, 7, and 8;
- n 4, 5, 6, 7, and 8;
- R is 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; 2-, and 3-, and 4-chloro; 2-, 3-, and 4-bromo; 2-, 3-, and 4- iodo; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2-, 3-, and 4-hydroxyl; 2-, 3-, and 4-amino; and 2-, 3-, and 4-dimethylamino.
- n 4, 5, 6, and 7.
- the tribenzyl product was dissolved in methanol (100 mL) and 5% Pd-C (100 mg) was added. The reaction suspension was shaken under hydrogen pressure ( ⁇ 50 psi) at room temperature overnight. The solid was separated by filtration and washed with hot methanol (5 ⁇ 50 mL). The combined methanol filtrates were evaporated to solid residue. The solid residue was slurried in cooled acetone and filtered. The yield of target product was 30-60%.
- the reaction mixture was refluxed two hours.
- the solvent was evaporated and solid residue was dissolved in water (50 mL) and extracted with chloroform (3 ⁇ 50 mL).
- Water solution was acidified to pH ⁇ 5 and concentrated (to volume of about 10 mL).
- the water solution or suspension was cooled down and precipitate was separated by filtration.
- the solid product was purified by crystallization from ethyl acetate. The yield was 40-60%.
- n 4, 5, 6, 7, and 8.
- R is 4-hydroxylaminocarbonyl; 4-methoxycarbonyl; 2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2,3 -difluoro; 2,4-difluoro; 2,5-difluoro; 2,6-difluoro; 1,2,3,-trifluoro, 3,4,5-trifluoro; 2,3,5,6-tetrafluoro; 2,3,4,5,6-pentafluoro
- n 4, 5, 6, 7, and 8.
- the reaction mixture was stirred at room temperature for an hour. The solvent was evaporated, the reside was dissolved in chloroform (300 mL), and the chloroform solution was washed with 10% hydrochloric acid (3 ⁇ 50 mL), 10% potassium hydroxide (3 ⁇ 50 mL), and water (3 ⁇ 50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated, yielding the pure monoester monoamide of dicarboxylic acid.
- the product was dissolved in 80% methanol with potassium hydroxide (0.56 g; 0.01 mol). The reaction mixture was refluxed two hours and evaporated to solid residue. The residue was dissolved in water ( ⁇ 20 mL) and acidified to ⁇ pH 5 with 10% hydrochloric acid.
- the monoacid monoamide of the dicarboxylic acid was isolated by filtration of precipitate or extraction water solution with chloroform.
- the isolated monoacid monoamide of the dicarboxylic acid was mixed together with an equivalent amount of O-benzylhydroxylamine and 1,3-dicyclohexylcarbodiimide in pyridine ( ⁇ 100 mL per 0.01 mol of O-benzylhydroxylamine) and was stirred at room temperature overnight.
- the solvent was evaporated and the solid residue was partitioned between chloroform (500 mL) and 10% hydrochloric acid (300 mL).
- the organic layer was washed with water (3 ⁇ 100 mL) and dried over anhydrous magnesium sulfate.
- the solvent was evaporated to solid residue.
- the solid residue was dissolved in large amounts of tetrahydrofuran and filtered through a short column of silica gel.
- the crude product was dissolved in methanol (100 mL) and 5% Pd-C was added.
- the reaction suspension was shaken under hydrogen pressure ( ⁇ 50 psi) overnight.
- the catalyst was separated by filtration and filtrate was evaporated to solid residue.
- the solid residue was slurried in hexanes and filtered. Usually pure product was isolated in this way. If necessary further purification was achieved by column chromatography on silica gel with ethyl acetate-tetrahydrofuran. The yields were from 35% to 65%.
- R is 4-hydroxylaminocarbonyl; 4-methoxycarbonyl; 4-tetrazoyl; 2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2,3-difluoro; 2,4-difluoro; 2,5-difluoro; 2,6-difluoro; 1,2,3-trifluoro; 3,4,5-trifluoro; 2,4,5-trifluoro; 2,4,6-trifluoro; 2,3,6-trifluoro; 2,3,5,6-trifluoro; 2,3,4,5,6-pentafluoro; 2-, 3-, and 4-phenyl; 2-, 3-, and 4-benzyloxy; 4-hexyl; and 4-t-butyl;
- n 4, 5, 6, 7, and 8; and R is hydrogen or methyl.
- a diacid dichloride (0.01 mol) was added into a stirred solution of potassium hydroxide (1.68 g; 0.03 mol), aniline or N-methylaniline (0.01 mol), and dimethylamine hydrochloride (0.805 g; 0.01 mol) in 50% tetrahydrofuran (100 mL).
- the reaction mixture was stirred thirty minutes at room temperature.
- the solvent was partitioned between chloroform (400 mL) and water (300 mL).
- the organic layer was washed with 10% hydrochloric acid (3 ⁇ 100 mL), 10% potassium hydroxide (3 ⁇ 100 mL), and water (2 ⁇ 100 mL).
- the organic layer was dried over anhydrous magnesium sulfate and evaporated.
- the solid residue was slurried in hexanes and filtered. The yield were 25-34%.
Abstract
wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition and a therapeutically acceptable amount of the compound above.
Description
Throughout this application various publications are referenced by arabic numerals within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which normally govern proliferation and differentiation. For many years there have been two principal strategies for chemotherapeutic treatment of cancer: a) blocking hormone-dependent tumor cell proliferation by interference with the production of peripheral action of sex hormones; and b) killing cancer cells directly by exposing them to cytotoxic substances, which injure both neoplastic and normal cell populations.
Relatively recently, cancer therapy is also being attempted by the induction of terminal differentiation of the neoplastic cells (1). In cell culture models differentiation has been reported by exposure of cells to a variety of stimuli, including: cyclic AMP and retinoic acid (2,3), aclarubicin and other anthracyclines (4).
There is abundant evidence that neoplastic transformation does not necessarily destroy the potential of cancer cells to differentiate (1,5,6). There are many examples of tumor cells which do not respond to the normal regulators of proliferation and appear to be blocked in the expression of their differentiation program, and yet can be induced to differentiate and cease replicating. A variety of agents, including some relatively simple polar compounds (5,7-9), derivatives of vitamin D and retinoic acid (10-12), steroid hormones (13), growth factors (6,14), proteases (15,16), tumor promoters (17,18), and inhibitors of DNA or RNA synthesis (4,19-24), can induce various transformed cell lines and primary human tumor explants to express more differentiated characteristics.
Early studies by the present inventors identified a series of polar compounds that were effective inducers of differentiation in a number of transformed cell lines (8,9). Of these, the most effective inducer, was the hybrid polar/apolar compound N,N′-hexamethylene bisacetamide (HMBA) (9). The use of this polar/apolar compound to induce murine erythroleukemia cells (MELC) to undergo erythroid differentiation with suppression of oncogenicity has provided a useful model to study inducer-mediated differentiation of transformed cells (5,7-9). HMBA-induced MELC terminal erythroid differentiation is a multistep process. Upon addition of HMBA to MELC (745A-DS19) in culture, there is a latent period of 10 to 12 hours before commitment to terminal differentiation is detected. Commitment is defined as the capacity of cells to express terminal differentiation despite removal of inducer (25). Upon continued exposure to HMBA there is progressive recruitment of cells to differentiate. The present inventors have reported that MELC cell lines made resistant to relatively low levels of vincristine become markedly more sensitive to the inducing action of HMBA and can be induced to differentiate with little or no latent period (26).
HMBA is capable of inducing phenotypic changes consistent with differentiation in a broad variety of cells lines (5). The characteristics of the drug induced effect have been most extensively studied in the murine erythroleukemia cell system (MELC) (5,25,27,28). MELC induction of differentiation is both time and concentration dependent. The minimum concentration required to demonstrate an effect in vitro in most strains is 2 to 3 mM; the minimum duration of continuous exposure generally required to induce differentiation in a substantial portion (>20%) of the population without continuing drug exposure is about 36 hours.
The primary target of action of HMBA is not known. There is evidence that protein kinase C is involved in the pathway of inducer-mediated differentiation (29). The in vitro studies provided a basis for evaluating the potential of HMBA as a cytodifferentiation agent in the treatment of human cancers (30). Several phase I clinical trials with HMBA have been completed (31-36). Clinical trials have shown that this compound can induce a therapeutic response in patients with cancer (35,36). However, these phase I clinical trials also have demonstrated that the potential efficacy of HMBA is limited, in part, by dose-related toxicity which prevents achieving optimal blood levels and by the need for intravenous administration of large quantities of the agent, over prolonged periods.
Recently, the present inventors have reported a number of compounds related to HMBA with polar groups separated by apolar linkages that, on a molar basis, are as active (37) or 100 times more active than HMBA (38). As a class, however, it has been found that the symmetrical dimers such as HMBA and related compounds are not the best cytodifferentiating agents.
It has unexpectedly been found that the best compounds comprise two polar end groups separated by a flexible chain of methylene groups, wherein one or both of the polar end groups is a large hydrophobic group. Preferably, the polar end groups are different and only one is a large hydrophobic group. These compounds are unexpectedly a thousand time more active than HMBA and ten times more active than HMBA related compounds.
This new class of compounds of the present invention may be useful for selectively inducing terminal differentiation of neoplastic cells and therefore aid in treatment of tumors in patients.
wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
wherein each of R3 and R4 are independently the same as or different from each other are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
wherein R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; and n is an integer from about 4 to about 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; R is a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m, n, and o are independently the same as or different from each other and are each an integer from about 0 to about 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to 8.
wherein each of X and Y are independently, the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and n is an integer from about 0 to about 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, aryloxy, carbonylhydroxylamino, or fluoro group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
wherein each of R1 and R2 are independently the same as or different form each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
In addition, the present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation.
The present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of any of the compounds above.
wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridino group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8.
In the preferred embodiment of the compound above, R2 is a hydroxylamino, hydroxyl, amino, methylamino, dimethylamino, or methoxy group and n is 6. Most preferably, R4 is a hydrogen atom and R3 is a substituted or unsubstituted phenyl group.
The phenyl group may be substituted with a methyl, cyano, nitro, trifluoromethyl, amino, aminocarbonyl, methylcyano, chloro, fluoro, bromo, iodo, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl, hydroxyl, methyoxy, benzyloxy, phenylaminooxy, phenylmethoxy, phenylaminocarbonyl, methoxycarbonyl, methylaminocarbonyl, dimethylamino, dimethylaminocarbonyl, or hydroxylaminocarbonyl group.
In other preferred embodiments of the compound above, R4 is a hydrogen atom and R3 is a cyclohexyl group; R4 is a hydrogen atom and R3 is a methyoxy group; R3 and R4 each bond together to form a piperidine group; R4 is a hydrogen atom and R3 is a hydroxyl group; R4 is a hydrogen atom and R3 is a benzyloxy group; R4 is a hydrogen atom and R3 is a δ-pyridine group; R4 is a hydrogen atom and R3 is a β-pyridine group; R4 is a hydrogen atom and R3 is a α-pyridine group; R3 and R4 are both methyl groups; or R4 is a methyl group and R3 is a phenyl group.
wherein R is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; and n is an integer from about 4 to about 8.
In the preferred embodiment of the compound above, R is a substituted or unsubstituted phenylamino group. The phenylamino group may be substituted with a cyano, methylcyano, nitro, carboxyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, trifluoromethyl, hydroxylaminocarbonyl, N-hydroxylaminocarbonyl, methoxycarbonyl, chloro, fluoro, methyl, methoxy, 2,3-difluoro, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 2,6-difluoro, 3,5-difluoro, 2,6-difluoro, 2,3,6-trifluoro, 1,2,3-trifluoro, 3,4,5-trifluoro, 2,3,4,5-tetrafluoro, or 2,3,4,5,6-pentafluoro group.
In another embodiment of the compound above, R is a cyclohexylamino group.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; R is a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy-group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X, Y, and R is a hydroxyl group and each of m and n is 5.
wherein each of X and Y are independently the same as or different form each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m, n, and o are independently the same as or different from each other and are each an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X and Y is a hydroxyl group and each of R1 and R2 is a methyl group. Most preferably, each of n and o is 6, and m is 2.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X and Y is a hydroxyl group and each of m and n is 5.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, or aryloxy group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; and n is an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X and Y is a dimethylamino group and n is 4 or 5.
wherein each of X and Y are independently the same as or different from each other and are a hydroxyl, amino or hydroxylamino group, a substituted or unsubstituted alkyloxy, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group; each of R1 and R2 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl, aryl, alkyloxy, aryloxy, carbonylhydroxylamino, or fluoro group; and each of m and n are independently the same as or different from each other and are each an integer from about 0 to about 8.
In the preferred embodiment of the compound above, each of X and Y is a hydroxylamino group, R1 is a methyl group, R2 is a hydrogen atom, and each of m and n is 2. In another preferred embodiment, each of X and Y is a hydroxylamino group, R1 is a carbonylhydroxylamino group, R2 is a hydrogen atom, and each of m and n is 5. In a further preferred embodiment, each of X and Y is a hydroxylamino group, each of R1 and R2 is a fluoro group, and each of m and n is 2.
wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
Preferably, R1 is a phenylamino group and R2 is a hydroxylamino group.
wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
Preferably, R1 is phenylamino group and R2 is hydroxylamino group.
wherein each of R1 and R2 are independently the same as or different from each other and are a hydroxyl, alkyloxy, amino, hydroxylamino, alkylamino, dialkylamino, arylamino, alkylarylamino, alkyloxyamino, aryloxyamino, alkyloxyalkylamino, or aryloxyalkylamino group.
In the preferred embodiment, either R1 or R2 is a hydroxylamino group.
The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation.
The contacting must be performed continuously for a prolonged period of time, i.e. for at least 48 hours, preferably for about 4-5 days or longer.
The method may be practiced in vivo or in vitro. If the method is practiced in vitro, contacting may be effected by incubating the cells with the compound. The concentration of the compound in contact with the cells should be from about 1 μM to about 25 mM, preferably from 4 μM to about 5 mM. The concentration depends upon the individual compound and the state of the neoplastic cells.
The method may also comprise initially treating the cells with an antitumor agent so as to render them resistant to an antitumor agent and subsequently contacting the resulting resistant cells under suitable conditions with an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such cells.
The antitumor agent may be one of numerous chemotherapy agents such as an alkylating agent, an antimetabolite, a hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, mitotane, nitrosoureas or an imidazole carboxamide. Suitable agents are those agents which promote depolarization of tubulin. Preferably the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine. In embodiments where the antitumor agent is vincristine, the cells preferably are treated so that they are resistant to vincristine at a concentration of about 5 mg/ml. The treating of the cells to render them resistant to an antitumor agent may be effected by contacting the cells with the agent for a period of at least 3-5 days. The contacting of the resulting cells with any of the compounds above is performed as described previously.
The present invention also provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
The method of the present invention is intended for the treatment of human patients with tumors. However, it is also likely that the method would be effective in the treatment of tumors in other mammals. The term tumor is intended to include any cancer caused by the proliferation of neoplastic cells, such as lung cancer, acute lymphoid myeloma, bladder melanoma, renal carcinoma, breast carcinoma, or colorectal carcinoma. The administration of the compound to the patient may be effected orally or parenterally. To date administration intravenously has proven to be effective. The administration of the compound must be performed continuously for a prolonged period of time, such as for at least 3 days and preferably more than 5 days. In the most preferred embodiments, the administration is effected continuously for at least 10 days and is repeated at intervals wherein at each interval the administration is continuously effected for at least 10 days. For example, the administration may be effected at intervals as short as 5-10 days, up to about 25-35 days and continuously for at least 10 days during each such interval. The optimal interval period will vary depending on the type of patient and tumor. For example, in the incidence of acute leukemia, the so called myelodysplastic syndrome, continuous infusion would seem to be indicated so long as the patient tolerated the drug without toxicity and there was a positive response.
The amount of the compound administered to the patient is less than an amount which would cause toxicity in the patient. In the certain embodiments, the amount of the compound which is administered to the patient is less than the amount which causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compound. Preferably, the concentration of the compound in the patient's plasma is maintained at about 1.0 mM. It has been found with HMBA that administration of the compound in an amount from about 5 gm/m2/day to about 30 gm/m2/day, particularly about 20 gm/m2/day, is effective without producing toxicity in the patient. The optimal amount of the compound which should be administered to the patient in the practice of the present invention will depend on the particular compound used and the type of cancer being treated.
This invention, in addition to the above listed compounds, is intended to encompass the use of homologs and analogs of such compounds. In this context, homologs are molecules having substantial structural similarities to the above-descried compounds and analogs are molecules having substantial biological similarities regardless of structural similarities.
The method may also comprise initially administering to the patient an amount of an antitumor agent to render the cells resistant to an antitumor agent and subsequently administering to the patient an effective amount of any of the compounds above, effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
The antitumor agent may be one of numerous chemotherapy agents such as an alkylating agent, an antimetabolite, a hormonal agent, an antibiotic, colchicine, a vinca alkaloid, L-asparaginase, procarbazine, hydroxyurea, mitotane, nitrosoureas of an imidazole carboxamide. Suitable agents are those agents which promote depolarization of tubulin. Preferably the antitumor agent is colchicine or a vinca alkaloid; especially preferred are vinblastine and vincristine. In embodiments where the antitumor agent is vincristine, an amount is administered to render the cells are resistant to vincristine at a concentration of bout 5 mg/ml. The administration of the agent is performed essentially as described above for the administration of any of the compounds. Preferably, the administration of the agent is for a period of at least 3-5 days. The administration of any of the compounds above is performed as descried previously.
The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier, such as sterile pyrogen-free water, and a therapeutically acceptable amount of any of the compounds above. Preferably, the effective amount is an amount effective to selectively induce terminal differentiation of suitable neoplastic cells and less than an amount which causes toxicity in a patient.
Lastly, the present invention provides the pharmaceutical composition above in combination with an antitumor agent. The antitumor agent may be any of the agents previously described.
The invention is illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the claims, which follow thereafter.
MELC 745A-DS19 cells and the variants of MELC derived from this cell line, namely, the vincristine-resistant MELC V3.17 and VCR.C(2)15 cell lines (26), and the dimethylsulfoxide-resistant cell line, DR10 (39), were maintained in alpha minimal essential medium containing 10% fetal calf serum (16). Cell cultures for all experiments were initiated with cells in logarithmic growth phase (day 2 cultured cells) at a density of 105 cells/ml. Inducer compounds were added in the final concentrations indicated below, dissolved in culture medium without fetal calf serum unless otherwise indicated. Cell density and benzidine reactively were determined as described (16).
Commitment to terminal differentiation, characterized by limited cell division (colony size<32 cells) and accumulation of hemoglobin (benzidine reactive colonies) was assayed by a colony cloning assay using 2% methylcellulose as described (25) (see Table 1 for results). HL-60 human leukemia cells, derived from peripheral blood leukocytes of a patient with acute promyelocytic leukemia (40). Induced differentiation of HL-60 cells assayed by determining the proportion of cells that developed the capacity to reduce nitroblue tetrazolium (NBT) (41) (see Table 2 for results).
Chemistry
Preparation of PhCH2ONHOC(CH2)6COOCH3:
A solution of suberic acid monomethyl ester (1.9 g; 0.01 mol), oxaloyl chloride (1.75 mL; 2.54 g; 0.02 mol) and 0.1 mL DMF in benzene (200 mL) was stirred overnight at room temperature. The solvent was evaporated and oily residue was dissolved in chloroform (˜20 mL) and mixed together with chloroform solution (100 mL) of O-benzylhydroxylamine (2.46 g; 0.02 mol) and pyridine (1.6 mL; 1.68 g; 0.02 mol). The reaction mixture was stirred at room temperature overnight. The chloroform solution was washed with water (50 mL), 10% hydrochloric acid, and again with water (2×50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was slurried in hexanes (˜100 mL) and filtered. The yield of PhCH2ONHOC(CH2)6COOCH3 was 2.61 g (89%).
The above suberic acid monobenzyloxyamide monomethyl ester (1 g; 3.4 mol) was dissolved in dry methanol (50 mL) and 5% Pd-C (50 mg) was added. The black suspension was shaken under hydrogen pressure (˜50 psi) overnight at room temperature. The catalyst was separated by filtration, and filtrate was evaporated. The solid residue was slurried in hexanes (˜20 mL) and filtered. The yield of the monomethyl ester monohydroxamic acid of suberic acid was 900 mg (95%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.89 (s, broad, NHOH, 1H); 3.57 (s, CH3, 3H); 2.27 (t, J=7.4 Hz, CH2COOCH3, 2H); 1.91 (t, J=7.4 Hz, CH2CONHOH, 2H); 1.49 (m, 4H), 1.24(m, 4H).
Suberic acid monobenzyloxyamide monomethyl ester (1 g; 3.4 mmol) and potassium hydroxide (210 mg; 3.75 mmol) were dissolved in 10 mL of methanol-water (4:1) mixture. The reaction mixture was refluxed two hours and solvent was evaporated. The solid residue was dissolved in 5 mL water and acidified with conc. hydrochloric acid to pH˜5. White precipitate was filtered, dried and crystallized from ethyl acetate-hexanes. The yield of suberic acid monobenzyloxyamide was 820 mg (86%). The product was dissolved in methanol (50 mL) and 5% Pd-C (50 mg) was added. The reaction mixture was shaken under hydrogen pressure (50 psi) overnight. The catalyst was separated by filtration and filtrate was evaporated. The solid residue was slurried in hexanes and filtered. The yield of suberic acid monohydroxamic acid was 520 mg (81%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.96 (s, broad, COOH, 1H); 10.31 (s, NHOH, 1H); 8.63 (s, broad NHOH, 1H); 2.17 (s, J=7.4 Hz, CH2COOH, 2H); 1.91 (s, CH2CONHOH, 2H); 1.46 (m, 4H); 1.22 (m, 4H).
A pyridine (500 mL) solution of O-benzylhydroxylamine (2.46 g; 0.02 mol), the corresponding amine (0.02 mol) and suberoyl chloride was stirred at room temperature overnight. The solvent was evaporated and the semisolid residue was dissolved in 100 mL chloroform-methanol (4:1); the resulting solution was washed with water (2×100 mL), 10% hydrochloric acid (3×100 L), and again with water (2×100 mL). Organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was dissolved in methanol (100 mL) and 5% Pd-C was added. The black suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was separated by filtration, and the filtrate was evaporated. The target products were isolated by column chromatography on silica gel with ethyl acetate-tetrahydrofuran.
Yield 1.1 g (26%). 1H NMR (DMSO-D2, 200 MHz), δ(ppm) 10.93 (s, NHOCH3, 1H); 10.32 (s, NHOH, 1H); 8.66 (s, NHOH, 1H); 3.55 (s, CH3, 3H); 1.19 (t, J=7.6 Hz, CH2CO—,4H); 1.45 (m, 4H); 1.20 (m, 4H).
Yield 1.2 g (21%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.60 (s, broad, NHOH, 1H); 7.57 (d, J=7.6 Hz, NH—C6H11, 1 H), 3.40 (m, CH—NH, 1H); 1.99 (t, J=7Hz, CH2CONHC6H11, 2H; 1.91 (t, J=7.6 Hz, CH2CONHOH, 2H); 2.63 (m, 4H); 1.44 (m, 6H); 1.20 (m, 8H).
Yield 870 mg (20%); 1H NMR (DMSO-D6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.67 (s, broad, NHOH, 1H); 2.85 (d, J=30 Hz, N(CH3)2, 6H); 2.24 (t, J=7.4 Hz, CH2CON(CH3), 2H); 1.91 (t, J=7.4 Hz, CH2COONHOH, 2H); 1.50 (m, 4H); 1.20 (m, 4H).
Yield 1.4 g (27%) 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 8.67 (s, NHOH, 1H); 3.40 (2t, CH2N, 4H); 2.20 (t, J=7.4 Hz, CH2CON(CH2)5, 2H); 1.91 (t, J=7.4 Hz, CH2CONHOH, 2H); 1.10-1.60 (m, broad, 14H).
The chloroform (500 mL) solution of O-benzylhydroxylamine (1.23 g; 0.01 mol), O-(trimethylsilyl)hydroxylamine (1.1 g; 0.01 mol), pyridine (1.6 mL; 1.7 g; 0.02 mol) and suberoyl chloride (1.8 mL; 2.11 g; 0.01 mol) was stirred at room temperature overnight. The reaction suspension was diluted with methanol (100 mL), washed with 10% hydrochloric acid (3×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was subjected to chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1). The yield was 500 mg (17%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.09 (s, NHOCH2C6H5, 1H); 10.31 (s, NHOH, 1H); 8.67 (s, broad, NHOH, 1H); 7.36 (s, C6H5, 5H), 4.76 (s, CH2C6H5, 2H); 1.92 (t, J=7.4 Hz, CH2CO—, 4H); 1.45 (m, 4H); 1.20 (m, 4H).
Into a cooled solution of potassium hydroxide (2.24 g; 0.04 mol) and O-benzylhydroxylamine hydrochloride in 30 mL of tetrahydrofuran-water (1:1) mixture, 6-bromohexanoyl chloride (3.1 mL; 4.27 g; 0.02 mol) was added. The reaction mixture was stirred at room temperature for one hour. The solvent was evaporated and solid residue was partitioned between chloroform (200 mL) and water (100 mL). Chloroform layer was washed with 10% hydrochloric acid (3×50 mL) and water (2×50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The product was purified by crystallization from ethyl acetate-hexanes. The yield of N-benzyloxy-6-bromohexanoyl amide was 4.7 g (78%). A dimethylsulfoxide (250 mL) solution of N-benzyloxy-6-bromohexanoyl amide (4.5 g; 15 mmol) and sodium cyanide (7.35 g; 0.15 mol) was heated at 130° C. overnight. The solvent was evaporated and solid residue was partitioned between chloroform (300 mL) and water (300 mL). The chloroform layer was washed with water (5×100 mL), dried over anhydrous magnesium sulfate, and evaporated. The oily residue was purified by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1) as an eluent. The yield of N-benzyloxy-6-cyanohexanoylamide was 1.62 g (43%). The product was dissolved in methanol (50 mL) and 5% Pd-C (100 mg) was added. The black suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was isolated by filtration and filtrate was evaporated. The solid residue was slurried in hexanes (˜20 mL) and filtered. The yield of N-hydroxy-6-cyanohexanoylamide was 900 mg (overall yield 30%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.32 (s, NHOH, 1H); 8.65 (s, NHOH, 1H); 2.45 (t,J=7 Hz, CH2CN, 2H) 1.93 (t, J=7 Hz, CH2CONHOH, 2H); 1.49 (m, 4H); 1.33 (m, 2H).
A diacid dichloride (0.01 mol) was added into a cooled (0° C.) solution of potassium hydroxide (1.12 g: 0.02 mol) and corresponding amine (0.01 mol) in 30 mL of tetrahydrofuran-water (1:1) mixture. The reaction mixture was stirred at room temperature about one hour. Solvent was evaporated and the solid residue was partitioned between chloroform (300 mL) and water (300 mL). In some cases a small amount of methanol is necessary to dissolve all solid. The organic layer was washed with 10% potassium hydroxide (3×30 mL). The basic water extract was acidified with 10% hydrochloric acid. The precipitate was collected by filtration, dried and purified by crystallization from ethyl acetate or by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (4:1). The yields are from 20-37%.
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.97 (s, COOH, 1H); 9.84 (s, NH, 1H); 7.57 (d, J=7.4 Hz, ortho aromatic protons, 2H); 7.26 (t, J=8.4 Hz, meta aromatic protons 2H); 6.99 (t, J=7.4 Hz, para aromatic proton, 1H), 2.27 (t, J=7 Hz, CH2CONHPh, 2H); 2.18 (t, J=7.2 Hz, 2H); 1.52 (m, 4H); 1.28 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.95 (s, COOH, 1H); 10.20 (s, NH, 1H); 8.10 (s, aromatic proton, 1H); 7.75 (m, aromatic proton, 1H); 7.45 (m, aromatic proton, 2H); 2.28 (t, J=7.4 Hz, CH2CONHAr, 2H); 2.21 (t, J=7.2 Hz, CH2COOH, 2H); 1.46 (m, 4H); 1.20 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.95 (s, COOH, 1H); 10.29 (s, NH, 1H); 7.75 (s, aromatic protons, 4H); 2.33 (t, J=7.2 Hz, CH2CONHAr, 2H); 2.18 (t, J=7.4 Hz, CH2COOH, 2H); 1.53 (m, 4H); 1.27 (m, 4H).
1H NMR (DMSO-D6, 200 MHz), 11.98 (s, broad, COOH, 1H); 10.48 (s, NH, 1H); 8.21 (d, J=9.2 Hz, aromatic protons, 2H); 7.82 (d, J=9.2 Hz, aromatic proton 2H); 2.36 (t, J=7.4 Hz, CH2CONHAr, 2H); 2.18 (t, J=7.2 Hz, CH2COOH, 2H); 1.55 (m, 4H); 1.29 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 12.00 (s, broad COOH, 2H); 10.24 (s, NH, 1H); 8.38 (d, J=5.8 Hz, aromatic protons, 2H); 7.55 (d, J=5.8 Hz, aromatic protons, 2H); 2.33 (t, J=7.2 Hz, CH2CONHAr, 2H); 2.18 (t, J=7.2 Hz, CH2COOH); 1.52 (m, 4H); 1.27 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.95 (s, COOH, 1H); 7.58 (d, J=8 Hz); 3.50 (m, CH, 1H); 2.17 (t, J=7.2 Hz, CH2COOH, 2H); 2.00 (t, J=7 Hz, CH2CONH—, 2H); 1.60 (m, 4H); 1.46 (m, 6H); 1.20 (m, 8H).
wherein N=4, 5, 6, 7, and 8; R is hydrogen; 2-, 3-, and 4-cyano; 2-, 3-, and 4-nitro; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-trifluoromethyl; 2-, 3-, and 4-fluoro:
wherein R is 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; 2-, and 3-, and 4-chloro; 2-, 3-, and 4-bromo; 2-, 3-, and 4- iodo; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2-, 3-, and 4-hydroxyl; 2-, 3-, and 4-amino; and 2-, 3-, and 4-dimethylamino.
wherein n=4, 5, 6, and 7.
A pyridine (500 mL) suspension of O-benzylhydroxylamine hydrochloride (3.2 g; 0.02 mol) and the corresponding diacid dichloride (0.04 mol) was stirred at room temperature for three days. Water (10 mL) was added and stirring was continued overnight. The solvent was evaporated and solid residue was purified by column chromatography on silica gel in tetrahydrofuran-methanol. The diacid produce was dissolved in methanol (100 mL) and 5% Pd-C (100 mg) was added. The reaction suspension was shaken overnight under hydrogen pressure (˜50 psi). The catalyst was separated by filtration, solid residue was washed with hot methanol (5×50 ml). The combined methanolic filtrates were evaporated. The solid residue was slurried in acetone and filtered. The yield was 10-20%.
A pyridine (500 ml) solution of O-benzylhydroxylamine (2.46 g; 0.02 mol) and the corresponding dicarboxylic acid monobenzyl ester monoacid chloride (0.04 mol) was stirred at room temperature overnight. The solvent was evaporated. The semisolid residue was dissolved in chloroform (300 mL) and extracted with 5% hydrochloric acid (2×50 mL), 10% potassium hydroxide (3×100 mL), and water (2×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was purified by column chromatography on silica gel in ethyl acetate. The tribenzyl product was dissolved in methanol (100 mL) and 5% Pd-C (100 mg) was added. The reaction suspension was shaken under hydrogen pressure (˜50 psi) at room temperature overnight. The solid was separated by filtration and washed with hot methanol (5×50 mL). The combined methanol filtrates were evaporated to solid residue. The solid residue was slurried in cooled acetone and filtered. The yield of target product was 30-60%.
1H NMR (DMSO-d6, 200MHz), δ(ppm) 11.53 (s, COOH, 1H); 2.41 (t, J=7.2 Hz, CH2CON(OH)COCH2, 4H); 2.18 (t, J=7.0 Hz, CH2COOH, 4H); 1.52 (m, 8 h); 1.22 (m, H). MS (FAB, glycerin) 346(M+1)
A pyridine (500 mL) solution of the monomethyl ester monoacid chloride of dicarboxylic acid (0.02 mol) and N,N′-dimethyl-1, x-diaminoalkane (0.01 mol) was stirred at room temperature overnight. Solvent was evaporated and oily residue was dissolved in chloroform (300 mL). Chloroform solution was washed with water (3×50 mL), 10% potassium hydroxide (3×50 mL), 10% hydrochloric acid (3×50 mL), and again with water (3×50 mL). The organic layer was dried and evaporated. The oily residue was dissolved in potassium hydroxide (1.2 g; 0.021 mol) in 80% methanol (100 mL). The reaction mixture was refluxed two hours. The solvent was evaporated and solid residue was dissolved in water (50 mL) and extracted with chloroform (3×50 mL). Water solution was acidified to pH˜5 and concentrated (to volume of about 10 mL). The water solution or suspension was cooled down and precipitate was separated by filtration. The solid product was purified by crystallization from ethyl acetate. The yield was 40-60%.
1H NMR (CDCl2, 200 MHz), δ(ppm) 8.15 (s, broad, COOH, 2H); 3.52+3.45 (2s, CH2N, 4H); 3.01+2.93 (2s, CH3N, 6H); 2.30 (4t, CH2CO, 8H); 1.60 (m, 8H); 1.32 (m, 8H). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 3.44+3.336+3.36 (3s, CH2N, 4H); 2.94+2.90+2.79 (3s, CH2N, 6H); 2.27+2.23 +2.12 (3t, CH2CO, 8H); 1.46 (m, 8H); 1.23 (m, 8H).
A pyridine (500 mL) solution of 6-aminocapric acid (2.6 g; 0.02 mol) and terephthaloyl chloride (2g; 0.01 mol) was stirred at room temperature overnight (˜12 hours), and at 90° C. for 23 hours. The solvent was evaporated, and the solid residue was crystallized from water (10 mL) four times. The yield was 800 mg (19%). 1H NMR (DMSO-d6, 200 MH), δ(ppm) 12.8 (s, broad, COOH, 2H); 8.54+7.72 (2t, NH, 2H); 3.24+2.98 (2m, NHCH2, 4H); 220+2.03 (2m, CH2CO, 4H); 1.50 (m, 8H); 1.32 (m, 4H).
Into a mixture of aniline (2.75 g; 0.03 mol), hydroxy-lamine hydrochloride (2.08 g; 0.03 mol), and potassium hydroxide (5.50 g; 0.09 mol) in 50% tetrahydrofuran (100 mL) was slowly added at room temperature a tetrahydrofuran (20 mL) solution of terephthaloyl chloride (6g; 0.03 mol). The reaction suspension was stirred at room temperature for thirty minutes. The solvent was evaporated. The solid residue was slurried in hot methanol (1000 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and filtrate was evaporated. The solid residue was slurried in 20 mL cooled methanol and filtered. The white crystals were washed with ether (5×50 mL) and dried. The yield was 4.6 g (39%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 11.35 (s, broad, NHOH, 1H); 10.35 (s, NHPh, 1H); 9.19 (s, NHOH, 1H); 8.03 (d, J=8 Hz, terephthalic protons, 2H); 7.89 (d, J=8 Hz, terephthalic protons, 2H); 7.82 (d, J=7.4 Hz, ortho anilide protons, 2H); 7.34 (t, =7.4 Hz, meta anilide protons, 2H); 7.10 (t, J=7.4 Hz, para anilide proton, 1H).
A solution of 1,4-phenylenediacrylic acid (2.18 g; 0.01 mol) in thionyl chloride (50 mL; 8.55 g; 0.68 mol) was refluxed overnight. The excess of thionyl chloride was evaporated. The solid was dissolved in tetrahydrofuran (20 mL), and added to a cooled (0° C.) solution of potassium hydroxide (1.12 g; 0.02 mol) and aniline in 50% tetrahydrofuran. The reaction mixture was stirred at room temperature for thirty minutes. The solvent was evaporated. The solid residue was slurried in water and filtered. White crystals were dissolved in a small amount of methanol and purified on a silica gel column in tetrahydrofuran. The yield was 315 mg (10%). 1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.80 (s, NHOH, 1H); 10.23 (s, NHPh, 1H); 9.09 (s, NHOH, 1H); 7.69 (d, J=7.6 Hz, ortho anilide protons, 2H); 7.64 (s, phenylene protons, 4H), 7.55 (d, J=15.8 Hz, PhNHOCCH═CH—, 1H); 7.40 (d, J=15.8 Hz, HONHOCCH═CH—, 1H); 7.33 (t, J=7.8 Hz, meta anilide protons, 2H); 7.06 (t, J=7.2 Hz, para anilide protons, 1H); 6.89 (d, J=15.8 Hz, PhNHOCCH═CH—, 1H) 6.51 (d, J=15.8 Hz, HOHNOCCH═CH—, 1H).
wherein n=4, 5, 6, 7, and 8.
A chloroform solution of triethylamine (1.4 mL; 1.0 g; 0.01 mol), the corresponding amine (0.01 mol) and diacid dichloride (0.005 mol) was stirred at room temperature for five hours. If the reaction mixture was clear, it was washed with water (5×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated to a solid residue. If in the course of reaction a precipitate was formed, the precipitate was separated by filtration. White crystals from filtration or solid residue from evaporation were crystallized from ethyl acetate, tetrahydrofuran, methanol, or their mixture. The yields were from 60-90%.
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.23 (s, NH, 2H); 7.82 (d, J=9 Hz, aromatic protons, 4H), 7.60 (d, J=9 Hz, aromatic protons, 4H), 2.31 (t, J=7.4 Hz, CH2CO, 4H); 2.61 (m, 4H); 1.32 (m, 4H),
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.48 (s, NH, 2H); 8.18 (d, J=9.2 Hz, aromatic protons, 4H); 7.81 (d, J=9.2 Hz, aromatic protons, 4H0; 2.37 (t, J=7.2 Hz, CH2CO—, 4H); 1.60 (m, 4H); 1.33 (m, 4H),
1H NMR (DMSO-d6200 MHz), δ9.91 (s, NH, 2H), 7.58 (d, J=8.6 Hz, aromatic protons, 4H); 7.26 (d, J=8.6 Hz, aromatic protons, 4H); 3.94 (s, CH2CN, 4H); 2.29 (t, J=7.4 Hz, CH2CO—, 4H); 1.60 (m, 4H); 1.31 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.08 (s, CONHAr, 2H); 7.79 (d, J=8.6 Hz, aromatic protons, 4H); 7.63 (d, J=8 Hz, aromatic protons, 4H), 7.22 (s, H3CHNCO—, 2H); 3.32 (s, CH3, 6H); 2.31 (t, J=7 Hz, CH2C—), 6H); 1.59 (m, 4H); 1.31 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.90 (s, broad, NHOH, 2H); 10.05 (s, NHAr, 2H); 8.90 (s, broad, NHOH, 2H); 7.68 (d, J=9 Hz, aromatic protons, 4H); 7.62 (d, J=9 Hz, aromatic protons, 4H); 2.31 (t, J=7.2 Hz, CH2CO—, 4H); 1.59 (m, 4H); 1.30 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.06 (s, broad, NH, 2H); 8.71 (d, J=2.6 Hz, aromatic protons, 2H); 7.31 (d+d, aromatic protons, 2H); 2.32 (t, J=7.4 Hz, CH2CO—, 4H); 1.59 (m, 4H); 1.33 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 12.00 (s, broad, NH, 2H); 7.43 (d, J=3.6 Hz, aromatic protons, 2H); 7.16 (d, J=3.6 Hz, aromatic protons 2H); 2.41 (t, J=7.2 Hz, CH2CONH—, 4H) 1.58 (m, 4H); 1.28 (m, 4H).
wherein n=4, 5, 6, 7, and 8; all compounds are symmetrical wherein R is 2-, 3-, and 4-cyano; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-nitro, 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; and 2-, 3-, and 4-trifluoromethyl;
wherein R is 4-hydroxylaminocarbonyl; 4-methoxycarbonyl; 2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2,3 -difluoro; 2,4-difluoro; 2,5-difluoro; 2,6-difluoro; 1,2,3,-trifluoro, 3,4,5-trifluoro; 2,3,5,6-tetrafluoro; 2,3,4,5,6-pentafluoro
wherein n=4, 5, 6, 7, and 8.
A diacid dichloride (0.01 mol) as added to a stirred solution of potassium hydroxide (1.68 g; 0.03 mol), hydroxylamine hydrochloride (0.7 g; 0.01 mol), and the corresponding aniline (0.01 mol) in 50 % tetrahydrofuran (100 mL). The resulting reaction mixture was stirred at room temperature thirty minutes, and solvent was evaporated to solid residue. The solid residue was slurried in methanol (˜100 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and evaporated to a solid residue. The product was purified by column chromatography on silica gel in ethyl acetate-tetrahydrofuran (in most cases 3:1). The yields were 15-30%.
A solution of corresponding monomethyl ester of dicarboxylic acid (0.01 mol), oxaloyl chloride (0.03 mol), and a few drops DMF in benzene (500 mL) was stirred at room temperature overnight. The solvent was evaporated and the oily residue was dissolved in dry benzene (3×50 mL) and evaporated again. The tetrahydrofuran (50 mL) solution of monoester monoacid chloride of the corresponding dicarboxylic acid was slowly added to a cooled solution of the corresponding amine (0.01 mol) and pyridine (1.6 mL; 1.6 g; 0.02 mol) in tetrahydrofuran (200 mL). The reaction mixture was stirred at room temperature for an hour. The solvent was evaporated, the reside was dissolved in chloroform (300 mL), and the chloroform solution was washed with 10% hydrochloric acid (3×50 mL), 10% potassium hydroxide (3×50 mL), and water (3×50 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated, yielding the pure monoester monoamide of dicarboxylic acid. The product was dissolved in 80% methanol with potassium hydroxide (0.56 g; 0.01 mol). The reaction mixture was refluxed two hours and evaporated to solid residue. The residue was dissolved in water (˜20 mL) and acidified to ˜pH 5 with 10% hydrochloric acid. The monoacid monoamide of the dicarboxylic acid was isolated by filtration of precipitate or extraction water solution with chloroform. The isolated monoacid monoamide of the dicarboxylic acid was mixed together with an equivalent amount of O-benzylhydroxylamine and 1,3-dicyclohexylcarbodiimide in pyridine (˜100 mL per 0.01 mol of O-benzylhydroxylamine) and was stirred at room temperature overnight. The solvent was evaporated and the solid residue was partitioned between chloroform (500 mL) and 10% hydrochloric acid (300 mL). The organic layer was washed with water (3×100 mL) and dried over anhydrous magnesium sulfate. The solvent was evaporated to solid residue. The solid residue was dissolved in large amounts of tetrahydrofuran and filtered through a short column of silica gel. The crude product was dissolved in methanol (100 mL) and 5% Pd-C was added. The reaction suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was separated by filtration and filtrate was evaporated to solid residue. The solid residue was slurried in hexanes and filtered. Mostly pure product was isolated in this way. If necessary further purification was achieved by column chromatography on silica gel with ethyl acetate-tetrahydrofuran. The yields were from 35% to 65%.
A pyridine (500 mL solution of O-benzylhydroxylamine (1.23; 0.01 mol), the corresponding amine (0.01 mol), and the dichloride of the dicarboxylic acid (0.01 mol) was stirred at room temperature overnight. The solvent was evaporated and the white solid residue contains, judged by 1H NMR, two symmetrical amides and a target unsymmetrical one. The solid residue was slurried in methanol and dried over anhydrous magnesium sulfate. The filtrate was evaporated and the solid residue was dissolved in methanol (˜100 mL). Into the methanol solution 5% Pd-C (100 mg) was added and the black suspension was shaken under hydrogen pressure (˜50 psi) overnight. The catalyst was separated by filtration and the filtrate was evaporated. The product was isolated by column chromatography on silica with ethyl acetate-tetrahydrofuran. The yields were from 20% to 35%.
A chloroform solution of triethylamine (3mL; 2.18 g; 0.0215 mol), the corresponding amine (0.01 mol), O-trimethylsilyl)hydroxylamine (1.05 g, 0.01 mol), and the corresponding diacid chloride of the dicarboxylic acid (0.01 mol) was stirred at room temperature overnight. The solvent was evaporated, the residue was dissolved in methanol (˜10 mL), and into the methanol solution 10% ammonium chloride (˜10 mL) was added. The resulting suspension was stirred at 50° C. for two hours. The solvent was evaporated. The solid residue was slurried in methanol (300 mL) and dried over anhydrous magnesium sulfate. The methanol solution was separated by filtration and evaporated to a solid residue. The product was isolated by silica gel column chromatography with ethyl acetate-tetrahydrofuran. The yields were 20-33%.
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 9.83 (s, NHPh, 1H); 8.64 (d, NHOH, 2H); 7.57 (d, J=8.2 Hz, ortho aromatic protons, 2H); 7.26 (t, J=8.4 Hz, meta aromatic protons, 2H), 6.99 (t, J=7.4 Hz, para aromatic protons, 1H); 2.27 (t, J=7.4 Hz, CH2CONHPh, 2H); 1.93 (t, J=7.2 Hz, CH2CONHOH, 2H); 1.52 (m, 4H); 1.26 (m, 4H). MS (Fab, Glycerin) 172, 204, 232, 249, 265, (100% M+1).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 10.08 (s, NHPh, 1H); 8.64 (s, NHOH, 1H); 7.78 (d, J=7.6 Hz, aromatic protons, 1H); 7.66 (t, J=7.4 Hz, aromatic protons, 1H); 7.48 (d, J=7.8 Hz, aromatic protons, 1H); 7.29 (t, J=7.4 Hz, aromatic protons, 1H); 2.34 (t, J=7 Hz, CH2CONHAr, 2H); 1.93 (t, J=7.4 Hz, CH2CONHOH, 2H); 1.58 (m, 4H); 1.27 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.31 (s, NHOH, 1H); 10.21 (s, NHPh, 1H); 8.65 (s, NHOH, 1H); 8.09 (s, aromatic proton, 1H); 7.77 (m, aromatic proton, 1H); 7.49 (m, aromatic proton, 1H); 2.31 (t, J=7.2 Hz, CH2CONHAr, 2H); 1.93 (t, J=7.2 Hz, CH2CONHOH, 2H); 1.51 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.35 (s, NHAr, 1H); 10.31 (s, NHOH, 1H); 8.63 (s, NHOH-+aromatic proton 2H); 7.88 (d, J=8 Hz, aromatic protons 2H); 7.57 (t, J=8 Hz, aromatic proton, 1H); 2.33 (t, J=7.6 Hz, CH2CONHAr, 2H); 1.93 (t, J=7.4 Hz, CH2CONHOH, 2H), 1.52 (m, 4H); 1.27 (m, 4H),
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.33 (s, NHOH, 1H); 10.15 (s, NHAr, 1H); 10.09 (s, NHPh, 1H); 8.66 (s, NHOH, 1H); 7.91 (d, J=8.6 Hz, aromatic protons 2H); 7.76 (d, J=7.8 Hz, ortho aniline protons, 2H); 7.71 (d, J=8.6 Hz, aromatic protons, 2H); 7.33 (t, J=7.6 Hz, meta anilide protons, 2H); 7.07 (t, J=7.4 Hz, para anilide protons); 2.33 (t, J=7.5 Hz, CH2NHAr, 2H); 1.93 (t, J=7.2 Hz, CH2CNHH, 2H); 1.51 (m, 4H); 1.28 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 10.32 (s, NHOH, 1H); 10.21 (s, NHAr, 1H); 8.65 (s, NHOH, 1H); 7.31 (d of d, J=10 Hz(2.2 Hz), aromatic protons, 2H); 6.84 (t of t, J=9.4 Hz(2.4Hz), aromatic protons, 1H); 2.29 (t, CH2CONHAr, 2H); 1.93 (t, J=7.2 Hz, CH2CONHOH, 2H); 1.51 (m, 4H); 1.26 (m, 4H).
wherein n=4, 5, 6, 7, and 8; and R is 2-, 3-, and 4-cyano; 2-, 3-, and 4-methylcyano; 2-, 3-, and 4-nitro; 2-, 3-, and 4-carboxy; 2-, 3-, and 4-aminocarbonyl; 2-, 3-, and 4-methylaminocarbonyl; 2-, 3-, and 4-dimethylaminocarbonyl; and 2-, 3-, and 4-trifluoromethyl;
wherein R is 4-hydroxylaminocarbonyl; 4-methoxycarbonyl; 4-tetrazoyl; 2-, 3-, and 4-chloro; 2-, 3-, and 4-fluoro; 2-, 3-, and 4-methyl; 2-, 3-, and 4-methoxy; 2,3-difluoro; 2,4-difluoro; 2,5-difluoro; 2,6-difluoro; 1,2,3-trifluoro; 3,4,5-trifluoro; 2,4,5-trifluoro; 2,4,6-trifluoro; 2,3,6-trifluoro; 2,3,5,6-trifluoro; 2,3,4,5,6-pentafluoro; 2-, 3-, and 4-phenyl; 2-, 3-, and 4-benzyloxy; 4-hexyl; and 4-t-butyl;
wherein n=4, 5, 6, 7, and 8; and R is hydrogen or methyl.
A diacid dichloride (0.01 mol) was added into a stirred solution of potassium hydroxide (1.68 g; 0.03 mol), aniline or N-methylaniline (0.01 mol), and dimethylamine hydrochloride (0.805 g; 0.01 mol) in 50% tetrahydrofuran (100 mL). The reaction mixture was stirred thirty minutes at room temperature. The solvent was partitioned between chloroform (400 mL) and water (300 mL). The organic layer was washed with 10% hydrochloric acid (3×100 mL), 10% potassium hydroxide (3×100 mL), and water (2×100 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated. The solid residue was slurried in hexanes and filtered. The yield were 25-34%.
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 9.82 (s, NHPh, 1H); 7.58 (d, J=7.6 Hz, ortho aromatic protons, 2H); 7.26 (t, J=7.4 Hz, meta aromatic protons, 2H); 6.99 (t, J=7.4 Hz, para aromatic proton, 1H); 2.85 (d, J=28 Hz, N(CH3)2, 6 H); 2.28 (t, J=7.2 Hz, CH2CO, 2H); 2.24 (t, J=7.4 Hz, CH2CO, 2H); 1.51 (m, 4H); 1.29 (m, 4H).
1H NMR (DMSO-d6, 200 MHz), δ(ppm) 7.30 (m, C6H5, 5H); 3.13 (s, H3CNPh, 3H); 2.83 (d, J=26 Hz, N(CH3)2, 6H); 2.17 (t, J=7.6 Hz, CH2CON(CH3)2, 2H); 1.98 (t, J=7.4 Hz, CH2CON(CH3)Ph, 2H); 1.41 (m, 4H); 1.11 (m, 4H).
TABLE 1 | ||||
Benzidine | ||||
Mol. | Optimal | Reactive | ||
CPD | Structure | Weight | Conc. (μM) | Cells (%) |
|
||||
1 | n = 4 (known compound) | 236 | 80 | 70 |
2 | n = 5 | 250 | 20 | 84 |
3 | n = 6 | 264 | 2.5 | 70 |
4 | n = 7 | 278 | 20 | 8 |
5 | n = 8 | 292 | 20 | 15 |
6 |
|
274 | 31 | 44 |
7 |
|
274 | 31 | 52 |
8 |
|
294 | 12.5 | 32 |
9 |
|
225 | 50 | 20 |
10 |
|
355 | 250 | 26 |
11 |
|
216 | 60 | 53 |
12 |
|
189 | 250 | 35 |
13 |
|
203 | 60 | 17 |
14 |
|
156 | 125 | 30 |
15 |
|
218 | 20 | 43 |
16 |
|
270 | 8 | 35 |
17 |
|
256 | 62 | 30 |
18 |
|
260 | 31 | 38 |
19 |
|
278 | 5 | 24 |
|
||||
20 | R = 4-methyl | 273 | 20 | 52 |
21 | R = 4-cyano | 289 | 7 | 70 |
22 | R = 3-cyano | 289 | 5 | 55 |
23 | R = 2-cyano | 289 | 16 | 65 |
24 | R = 3-nitro | 309 | 5 | 30 |
25 | R = 4-nitro | 309 | 0.8 | 30 |
26 | R = 3-trifluoromethyl | 332 | 30 | 30 |
27 | R = 4-trifluoromethyl | 332 | 5 | 47 |
28 | R = 2-amino | 279 | 20 | 54 |
29 | R = 4-cyanomethyl | 303 | 1 | 30 |
30 | R = 3-chloro | 298.5 | 2 | 33 |
31 | R = 4-azido (N3) | 304 | 2 | 47 |
32 | R = 2-fluoro | 282 | 4 | 65 |
33 | R = 3-fluoro | 282 | 1 | 25 |
34 | R = 4-fluoro | 282 | 4 | 43 |
35 | R = 4-benzyloxy | 370 | 4 | 20 |
36 | R = 4-methyoxycarbonyl | 322 | 4 | 28 |
37 | R = 4-methylaminocarbonyl | 321 | 30 | 16 |
38 | R = 2-bromo | 343 | 8 | 45 |
39 | R = 2-chloro | 298.5 | 4 | 34 |
40 | R = 4-bromo | 343 | 1.6 | 47 |
41 | R = 2,3-difluoro | 300 | 8 | 24 |
42 | R = 2,4,5-trifluoro | 318 | 8 | 36 |
43 | R = 2,3,6-trifluoro | 318 | 31 | 53 |
44 | R = 2,4,6-trifluoro | 318 | 16 | 47 |
45 | R = 2,4-difluoro | 300 | 6 | 60 |
46 | R = 2,3,4,5,6-pentafluoro | 354 | 31 | 53 |
47 | R = 3,4-difluoro | 300 | 4 | 61 |
48 | R = 3,4,5-trifluoro | 318 | 8 | 55 |
49 | R = 2,5-difluoro | 300 | 4 | 70 |
50 | R = 3,5-difluoro | 300 | 2 | 73 |
51 | R = 2-methoxy | 294 | 8 | 36 |
52 | R = 3-methoxy | 294 | 6 | 38 |
53 | R = 4-methoxy | 294 | 6 | 37 |
54 |
|
290 | 20 | 40 |
55 |
|
256 | 30 | 53 |
|
||||
56 | R = tri-fluoromethyl | 460 | 50 | 20 |
57 | R = 4(N)-hydroxylaminocarbonyl | 442 | 8 | 10 |
58 | R = 4-cyanomethyl | 402 | 50 | 25 |
59 | R = 2,4-difluoro | 396 | 500 | 54 |
60 | R = 2,6-difluoro | 396 | 100 | 21 |
61 | R = 3,5-difluoro | 396 | 125 | 31 |
62 | R = 2,3,6-trifluoro | 432 | 250 | 28 |
63 | R = 2,4,6-trifluoro | 432 | 125 | 35 |
64 | R = 2,3,4,5,6-pentafluoro | 504 | 125 | 13 |
65 | R = 4-nitro | 414 | 25 | 14 |
66 |
|
270 | 1250 | 80 |
67 |
|
256 | 2500 | 90 |
68 |
|
204 | 125 | 56 |
69 |
|
333 | 60 | 40 |
70 |
|
226 | 160 | 19 |
|
||||
71 | n = 4 | 310 | 100 | 8 |
72 | n = 5 | 324 | 250 | 10 |
73 | n = 6 | 338 | 50 | 7 |
74 | n = 7 | 352 | 100 | 10 |
75 | n = 8 | 366 | 100 | 10 |
TABLE 2 |
Induction of Differentiation of HL-60 |
Mol. | Optimal | NBT | |||
CPD | Weight | Conc. (μM) | Positive (%) | ||
2 | 250 | 7 | 22 | ||
3 | 264 | 1 | 21 | ||
6 | 274 | 20 | 30 | ||
7 | 274 | 20 | 21 | ||
22 | 289 | 1.7 | 28 | ||
21 | 289 | 2 | 6 | ||
26 | 332 | 6 | 27 | ||
25 | 309 | 3 | 18 | ||
36 | 322 | 1 | 32 | ||
31 | 304 | 2.5 | 7 | ||
29 | 303 | 1 | 15 | ||
43 | 318 | 2 | 20 | ||
1. Sporn, M. B., Roberts, A. B., and Driscoll, J. S. (1985) in Cancer: Principles and Practice of Oncology, eds. Hellman, S., Rosenberg, S. A., and DeVita, V. T., Jr., Ed. 2, (J. B. Lippincott, Philadelphia), P. 49.
2. Breitman, T. R., Selonick, S. E., and Collins, S. J. (1980) Proc. Natl. Acad. Sci. USA 77: 2936-2940.
3. Olsson, I. L. and Breitman, T. R. (1982) Cancer Res. 42: 3924-3927.
4. Schwartz, E. L. and Sartorelli, A. C. (1982) Cancer Res. 42: 2651-2655.
5. Marks, P. A., Sheffery, M., and Rifkind, R. A. (1987) Cancer Res. 47: 659.
6. Sachs, L. (1978) Nature (Lond.) 274: 535.
7. Friend, C., Scher, W., Holland, J. W., and Sato, T. (1971) Proc. Natl. Acad. Sci. (USA) 68: 378-382.
8. Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R. A., and Marks, P. A. (1975) Proc. Natl. Acad. Sci. (USA) 72: 1003-1006.
9. Reuben, R. C., Wife, R. L., Breslow, R., Rifkind, R. A., and Marks, P. A. (1976) Proc. Natl. Acad. Sci. (USA) 73: 862-866.
10. Abe, E. Miyaura, C., Sakagami, H., Takeda, M., Konno K., Yamazaki, T., Yoshika, S., and Suda, T. (1981) Proc. Natl. Acad, Sci. (USA) 78: 4990-4994.
11. Schwartz, E. L., Snoddy, J. R., Kreutter, D., Rasmussen, H., and Sartorelli, A. C. (1983) Proc. Am. Assoc. Cancer Res. 24: 18.
12. Tanenaga, K., Hozumi, M., and Sakagami, Y. (1980) Cancer Res. 40: 914-919.
13. Lotem, J. and Sachs, L. (1975) Int. J. Cancer 15: 731-740.
14. Metcalf, D. (1985) Science, 229: 16-22.
15. Scher, W., Scher, B. M., and Waxman, S. (1983) Exp. Hematol. 11: 490-498.
16. Scher, W., Scher, B. M., and Waxman, S. (1982) Biochem. & Biophys. Res. Comm. 109: 348-354.
17. Huberman, E. and Callaham, M. F. (1979) Proc. Natl. Acad. Sci. (USA) 76: 1293-1297.
18. Lottem, J. and Sachs, L. (1979) Proc. Natl. Acad. Sci. (USA) 76: 5158-5162.
19. Terada, M., Epner, E., Nudel, U., Salmon, J., Fibach, E., Rifkind, R. A., and Marks, P. A. (1978) Proc. Natl. Acad. Sci. (USA) 75: 2795-2799.
20. Morin, M. J. and Sartorelli, A. C. (1984) Cancer Res. 44: 2807-2812.
21. Schwartz, E. L., Brown, B. J., Nierenberg, M., Marsh, J. C., and Sartorelli, A. C. (1983) Cancer Res. 43: 2725-2730.
22. Sugano, H., Furusawa, M., Kawaguchi, T., and Ikawa, Y. (1973) Bibl. Hematol. 39: 943-954.
23. Ebert, P. S., Wars, I., and Buell, D. N. (1976) Cancer Res. 36: 1809-1813.
24. Hayashi, M., Okabe, J., and Hozumi, M. (1979) Gann 70: 235-238.
25. Fibach, E., Reuben, R. C., Rifkind, R. A., and Marks, P. A. (1977) Cancer Res. 37: 440-444.
26. Melloni, E., Pontremoli, S., Damiani, G., Viotti, P., Weich, N., Rifkind, R. A., and Marks, P. A. (1988) Proc. Natl. Acad. Sci. (USA) 85: 3835-3839.
27. Reuben, R., Khanna, P. L., Gazitt, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. (1978) J. Biol. Chem. 253: 4214-4218.
28. Marks, P. A. and Rifkind, R. A. (1988) International Journal of Cell Cloning 6: 230-240.
29. Melloni, E., Pontremoli, S., Michetti, M., Sacco, O., Cakiroglu, A. G., Jackson, J. F., Rifkind, R. A., and Marks, P. A. (1987) Proc. Natl. Acad. Sciences (USA) 84: 5282-5286.
30. Marks, P. A. and Rifkind, R. A. (1984) Cancer 54: 2766-2769.
31. Egorin, M. J., Sigman, L. M. VanEcho, D. A., Forrest, A., Whitacre, M. Y., and Aisner, J. (1987) Cancer. Res. 47: 617-623.
32. Rowinsky, E. W., Ettinger, D. S., Grochow, L. B., Brundrett, R. B., Cates, A. E., and Donehower, R. C. (1986) J. Clin. Oncol. 4: 1835-1844.
33. Rowinsky, E. L. Ettinger, D. S., McGuire, W. P., Noe, D. A., Grochow, L. B., and Donehower, R. C. (1987) Cancer Res. 47: 5788-5795.
34. Callery, P. S., Egorin, M. J., Geelhaar, L. A., and Nayer, M. S. B. (1986) Cancer Res. 46: 4900-4903.
35. Young, C. W. Fanucchi, M. P., Walsh, T. B., Blatzer, L., Yaldaie, S., Stevens, Y. W., Gordon, C., Tong, W., Rifkind, R. A., and Marks, P. A. (1988) Cancer Res. 48: 7304-7309.
36. Andreeff, M., Young, C., Clarkson, B., Fetten, J., Rifkind, R. A., and Marks, P. A. (1988) Blood 72: 186a.
37. Marks, P. A., Breslow, R., Rifkind, R. A., Ngo, L., and Singh, R. (1989) Proc. Natl. Acad. Sci. (USA) 86: 6358-6362.
38. Breslow, R., Jursic, B., Yan, Z. F., Friedman, E., Leng, L., Ngo, L., Rifkind, R. A., and Marks, P. A. (1991) Proc. Natl. Acad. Sci. (USA) 88: 5542-5546.
39. Ohta, Y., Tanaka, M., Terada, M., Miller, O. J., Bank, A., Marks, P. A., and Rifkind, R. A. (1976) Proc. Natl. Acad. Sci. (USA) 73: 1232-1236.
40. Collins, S. J., Gallo, R. C., and Gallagher, R. E. (1978) Nature (London) 270: 405-409.
41. Synder, S. W., Egorin, M. J., Geelhaar, L. A., Hamburger, A. W., and Callery, P. S. (1988) Cancer Res. 48; 3613-3616.
Claims (24)
wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is and are a substituted or unsubstituted cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, or alkyloxy group; and n is an integer from about 4 to about 8.
wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group; R2 is a hydroxylamino, hydroxyl, amino, alkylamino, or alkyloxy group; and n is an integer from about 4 5to about 87; and R3 —N—R 4 and R 2 are different.
3. A compound of claim 2 , wherein R2 is a hydroxylamino, hydroxyl, amino, methylamino, or methoxy group and n is 6.
4. A compound of claim 3 , wherein R4 is a hydrogen atom and R3 is a substituted or unsubstituted phenyl group.
5. A compound of claim 4 , wherein the phenyl group is substituted with a methyl, cyano, nitro, trifluoromethyl, amino, aminocarbonyl, metylcyano, chloro, fluoro, bromo, iodo, 2,3-difluoro, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 3,5-difluoro, 2,6-difluoro, 1,2,3-trifluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 3,4,5-trifluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6-pentafluoro, azido, hexyl, t-butyl, phenyl, carboxyl, hydroxyl, methyoxy methoxy, phenyloxy, benzyloxy, phenylaminooxy, phenylaminocarbonyl, methyoxycarbonyl methoxycarbonyl, methylaminocarbonyl, dimethylamino, dimethylaminocarbonyl, or hydroxylaminocarbonyl group.
6. A compound of claim 3 , wherein R4 is a hydrogen atom and R3 is a cyclohexyl group.
7. A compound of claim 3 , wherein R4 is a hydrogen atom and R3 is a methyoxy methoxy group.
8. A compound of claim 3 , wherein R3 and R4 bond together to form a piperidine group.
9. A compound of claim 3 , wherein R4 is a hydrogen atom and R3 is a hydroxyl group.
10. A compound of claim 3 , wherein R4 is a hydrogen atom and R3 is a benzyloxy group.
11. A compound of claim 3 2, wherein R4 is a hydrogen atom and R3 is a δ-pyridine γ-pyridine group.
12. A compound of claim 3 2, wherein R4 is a hydrogen atom and R3 is a β-pyridine group.
13. A compound of claim 3 2, wherein R4 is a hydrogen atom and R3 is a α-pyridine group.
14. A compound of claim 3 , wherein R3 and R4 are both methyl groups.
15. A compound of claim 3 , wherein R4 is a methyl group and R3 is a phenyl group.
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 2 .
17. A pharmaceutical composition of claim 16 in combination with an antitumor agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/004,411 USRE38506E1 (en) | 1991-10-04 | 2001-11-02 | Potent inducers of terminal differentiation and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/771,760 US5369108A (en) | 1991-10-04 | 1991-10-04 | Potent inducers of terminal differentiation and methods of use thereof |
US10/004,411 USRE38506E1 (en) | 1991-10-04 | 2001-11-02 | Potent inducers of terminal differentiation and methods of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/771,760 Reissue US5369108A (en) | 1991-10-04 | 1991-10-04 | Potent inducers of terminal differentiation and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE38506E1 true USRE38506E1 (en) | 2004-04-20 |
Family
ID=32072620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/004,411 Expired - Lifetime USRE38506E1 (en) | 1991-10-04 | 2001-11-02 | Potent inducers of terminal differentiation and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE38506E1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072735A1 (en) * | 2002-03-04 | 2004-04-15 | Richon Victoria M. | Methods of inducing terminal differentiation |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20060009526A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
US20060079551A1 (en) * | 2001-10-16 | 2006-04-13 | Richon Victoria M | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
US20070197473A1 (en) * | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
US20070197568A1 (en) * | 2005-11-04 | 2007-08-23 | Paul Bunn | Methods of using SAHA and Erlotinib for treating cancer |
US20080132575A1 (en) * | 2005-05-20 | 2008-06-05 | Jeannie Chow Wong | Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same |
US20080249179A1 (en) * | 2002-03-04 | 2008-10-09 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20090012175A1 (en) * | 2003-08-26 | 2009-01-08 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20090054720A1 (en) * | 2002-04-15 | 2009-02-26 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
US7517701B2 (en) | 2004-09-30 | 2009-04-14 | Mds Analytical Technologies (Us) Inc. | Luminescent lanthanide complexes |
US20100113392A1 (en) * | 2006-11-03 | 2010-05-06 | Badros Ashraf Z | Methods of using saha and bortezomib for treating multiple myeloma |
US20100113602A1 (en) * | 2007-02-27 | 2010-05-06 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
EP2236503A1 (en) | 2009-04-03 | 2010-10-06 | NatureWise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
US20100256401A1 (en) * | 2009-04-03 | 2010-10-07 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
EP2277387A1 (en) | 2009-07-22 | 2011-01-26 | NatureWise Biotech & Medicals Corporation | New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly |
WO2011056542A1 (en) | 2009-10-26 | 2011-05-12 | Ramot At Tel-Aviv University Ltd. | Cancer therapy with combinations of fts with hdac inhibitors |
WO2012120262A1 (en) | 2011-03-09 | 2012-09-13 | Larsson Pia | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
WO2014018625A1 (en) | 2012-07-25 | 2014-01-30 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
US9199923B2 (en) | 2006-02-14 | 2015-12-01 | President And Fellows Of Harvard College | Histone deacetylase inhibitors |
US9650379B2 (en) | 2013-12-12 | 2017-05-16 | Chong Kun Dang Pharmaceutical Corp. | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US11420950B2 (en) | 2015-05-22 | 2022-08-23 | Chong Kun Dang Pharmaceutical Corp. | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2279560A (en) | 1940-05-08 | 1942-04-14 | Du Pont | Viscous hydrocarbon oil |
US2279973A (en) | 1940-05-08 | 1942-04-14 | Du Pont | Stabilization of organic substances |
US2346665A (en) | 1940-05-08 | 1944-04-18 | Du Pont | Acid |
US2895991A (en) | 1959-07-21 | New chloromethylated amlides | ||
CH421933A (en) | 1964-02-03 | 1966-10-15 | Rhodiaceta | Manufacturing process for mixed amides of carboxylic acids |
US3450673A (en) | 1965-09-07 | 1969-06-17 | Ashland Oil Inc | Polyurethane compositions from diaminimides |
US3632783A (en) | 1969-05-27 | 1972-01-04 | Hall Co C P | Treatment of mosquito bites employing certain tetraalkyl diamides |
US3875301A (en) | 1974-04-30 | 1975-04-01 | Interx Research Corp | Useful tetraalkyl diamides in the treatment of poison ivy |
US4056524A (en) | 1974-04-09 | 1977-11-01 | Stauffer Chemical Company | Bis-substituted succinamides and their utility as herbicides |
US4442305A (en) | 1981-08-24 | 1984-04-10 | The United States Of America As Represented By The United States Department Of Energy | Polycatecholamide chelating agents |
EP0119428A2 (en) | 1983-02-18 | 1984-09-26 | Bayer Ag | Biscarboxamides for treating diseases, and process for their preparation |
US4480125A (en) | 1981-11-16 | 1984-10-30 | Polaroid Corporation | Itaconamide compounds and method of preparation |
US4537781A (en) | 1983-09-16 | 1985-08-27 | Research Corporation | Pharmaceutically useful malonamides |
DE3505250A1 (en) | 1984-02-17 | 1985-09-12 | Ppg Industries, Inc., Pittsburgh, Pa. | Aliphatically unsaturated bis(polybromophenyl)diamides |
US4611053A (en) | 1985-02-15 | 1986-09-09 | Sasa Michiyuki Mitch | Polyhydroxamide polymer |
US4614815A (en) | 1979-09-10 | 1986-09-30 | Anic S.P.A. | Process for producing diesterdiamides |
US4663353A (en) | 1979-03-06 | 1987-05-05 | The United States Of America As Represented By The Secretary Of Agriculture | Antibacterial fatty anilides |
US4801748A (en) | 1985-03-08 | 1989-01-31 | Osaka University | Catalytic process for preparing amide from nitrile, amine and water |
US4863967A (en) | 1986-06-16 | 1989-09-05 | Research Corporation | N,N-diaminophthalamides |
US4882346A (en) | 1987-06-16 | 1989-11-21 | The United States Of America As Reprsented By The Department Of Health And Human Services | Chemical differentiating agents |
GB2225012A (en) | 1988-11-18 | 1990-05-23 | Lorenzini Inst Biochim Ital | Indole derivatives, their preparation and use as medicaments |
WO1991000257A1 (en) | 1989-06-30 | 1991-01-10 | The Trustees Of Columbia University In The City Of New York | Novel potent inducers of terminal differentiation and methods of use thereof |
WO1991008191A1 (en) | 1989-11-14 | 1991-06-13 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of terminal differentiation and method of use thereof |
EP0433662A2 (en) | 1989-11-16 | 1991-06-26 | Warner-Lambert Company | Acat inhibitors |
US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5098598A (en) | 1988-12-24 | 1992-03-24 | Interox Chemicals Limited | Percarboxylic acids |
EP0478954A1 (en) | 1990-08-29 | 1992-04-08 | Merrell Pharmaceuticals Inc. | Serotonin 5HT1A and 5HT1D antagonists |
US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
EP0576941A1 (en) | 1992-06-30 | 1994-01-05 | Nisshin Flour Milling Co., Ltd. | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same |
US5330744A (en) | 1988-11-14 | 1994-07-19 | Sloan-Kettering Institute For Cancer Research | Method for increasing sensitivity to chemically induced terminal differentiation |
US5366982A (en) | 1990-07-24 | 1994-11-22 | Rhone-Poulenc Rorer S.A. | Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B4 antagonist activity, their preparation and use in pharmaceutical compositions |
-
2001
- 2001-11-02 US US10/004,411 patent/USRE38506E1/en not_active Expired - Lifetime
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2895991A (en) | 1959-07-21 | New chloromethylated amlides | ||
US2279560A (en) | 1940-05-08 | 1942-04-14 | Du Pont | Viscous hydrocarbon oil |
US2279973A (en) | 1940-05-08 | 1942-04-14 | Du Pont | Stabilization of organic substances |
US2346665A (en) | 1940-05-08 | 1944-04-18 | Du Pont | Acid |
CH421933A (en) | 1964-02-03 | 1966-10-15 | Rhodiaceta | Manufacturing process for mixed amides of carboxylic acids |
US3450673A (en) | 1965-09-07 | 1969-06-17 | Ashland Oil Inc | Polyurethane compositions from diaminimides |
US3632783A (en) | 1969-05-27 | 1972-01-04 | Hall Co C P | Treatment of mosquito bites employing certain tetraalkyl diamides |
US4056524A (en) | 1974-04-09 | 1977-11-01 | Stauffer Chemical Company | Bis-substituted succinamides and their utility as herbicides |
US3875301A (en) | 1974-04-30 | 1975-04-01 | Interx Research Corp | Useful tetraalkyl diamides in the treatment of poison ivy |
US4663353A (en) | 1979-03-06 | 1987-05-05 | The United States Of America As Represented By The Secretary Of Agriculture | Antibacterial fatty anilides |
US4614815A (en) | 1979-09-10 | 1986-09-30 | Anic S.P.A. | Process for producing diesterdiamides |
US4442305A (en) | 1981-08-24 | 1984-04-10 | The United States Of America As Represented By The United States Department Of Energy | Polycatecholamide chelating agents |
US4480125A (en) | 1981-11-16 | 1984-10-30 | Polaroid Corporation | Itaconamide compounds and method of preparation |
EP0119428A2 (en) | 1983-02-18 | 1984-09-26 | Bayer Ag | Biscarboxamides for treating diseases, and process for their preparation |
US4537781A (en) | 1983-09-16 | 1985-08-27 | Research Corporation | Pharmaceutically useful malonamides |
DE3505250A1 (en) | 1984-02-17 | 1985-09-12 | Ppg Industries, Inc., Pittsburgh, Pa. | Aliphatically unsaturated bis(polybromophenyl)diamides |
US4611053A (en) | 1985-02-15 | 1986-09-09 | Sasa Michiyuki Mitch | Polyhydroxamide polymer |
US4801748A (en) | 1985-03-08 | 1989-01-31 | Osaka University | Catalytic process for preparing amide from nitrile, amine and water |
US4863967A (en) | 1986-06-16 | 1989-09-05 | Research Corporation | N,N-diaminophthalamides |
US4882346A (en) | 1987-06-16 | 1989-11-21 | The United States Of America As Reprsented By The Department Of Health And Human Services | Chemical differentiating agents |
US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5330744A (en) | 1988-11-14 | 1994-07-19 | Sloan-Kettering Institute For Cancer Research | Method for increasing sensitivity to chemically induced terminal differentiation |
US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
GB2225012A (en) | 1988-11-18 | 1990-05-23 | Lorenzini Inst Biochim Ital | Indole derivatives, their preparation and use as medicaments |
US5098598A (en) | 1988-12-24 | 1992-03-24 | Interox Chemicals Limited | Percarboxylic acids |
WO1991000257A1 (en) | 1989-06-30 | 1991-01-10 | The Trustees Of Columbia University In The City Of New York | Novel potent inducers of terminal differentiation and methods of use thereof |
WO1991008191A1 (en) | 1989-11-14 | 1991-06-13 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of terminal differentiation and method of use thereof |
EP0433662A2 (en) | 1989-11-16 | 1991-06-26 | Warner-Lambert Company | Acat inhibitors |
US5366982A (en) | 1990-07-24 | 1994-11-22 | Rhone-Poulenc Rorer S.A. | Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B4 antagonist activity, their preparation and use in pharmaceutical compositions |
EP0478954A1 (en) | 1990-08-29 | 1992-04-08 | Merrell Pharmaceuticals Inc. | Serotonin 5HT1A and 5HT1D antagonists |
US5189179A (en) | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
EP0576941A1 (en) | 1992-06-30 | 1994-01-05 | Nisshin Flour Milling Co., Ltd. | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same |
Non-Patent Citations (37)
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879865B2 (en) | 2001-10-16 | 2011-02-01 | Sloan-Kettering Institute For Cancer Research | Treatment of cancer of the brain using histone deacetylase inhibitors |
US20110124731A1 (en) * | 2001-10-16 | 2011-05-26 | Sloan-Kettering Institute For Cancer Research | Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors |
US20060079551A1 (en) * | 2001-10-16 | 2006-04-13 | Richon Victoria M | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US20060009527A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
US20060009526A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
US20080114069A1 (en) * | 2002-03-04 | 2008-05-15 | Richon Victoria M | Methods of inducing terminal differentiation |
US20080194692A1 (en) * | 2002-03-04 | 2008-08-14 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
US8101663B2 (en) | 2002-03-04 | 2012-01-24 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20040072735A1 (en) * | 2002-03-04 | 2004-04-15 | Richon Victoria M. | Methods of inducing terminal differentiation |
US20100168242A1 (en) * | 2002-03-04 | 2010-07-01 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
US7375137B2 (en) | 2002-03-04 | 2008-05-20 | Merck Hdac Research, Llc | Methods of treating cancer with HDAC inhibitors |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US7399787B2 (en) | 2002-03-04 | 2008-07-15 | Merck Hdac Research, Llc | Methods of treating cancer with HDAC inhibitors |
US20040127522A1 (en) * | 2002-03-04 | 2004-07-01 | Chiao Judy H. | Methods of treating cancer with HDAC inhibitors |
US20080228005A1 (en) * | 2002-03-04 | 2008-09-18 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
US20080249179A1 (en) * | 2002-03-04 | 2008-10-09 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US7847122B2 (en) | 2002-03-04 | 2010-12-07 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US7851509B2 (en) | 2002-03-04 | 2010-12-14 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US7652069B2 (en) | 2002-03-04 | 2010-01-26 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20090054720A1 (en) * | 2002-04-15 | 2009-02-26 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
US20090012175A1 (en) * | 2003-08-26 | 2009-01-08 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7517701B2 (en) | 2004-09-30 | 2009-04-14 | Mds Analytical Technologies (Us) Inc. | Luminescent lanthanide complexes |
US8093295B2 (en) | 2005-05-20 | 2012-01-10 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
US20080132575A1 (en) * | 2005-05-20 | 2008-06-05 | Jeannie Chow Wong | Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same |
US20100119596A1 (en) * | 2005-05-20 | 2010-05-13 | Jeannie Chow Wong | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
US8450372B2 (en) | 2005-05-20 | 2013-05-28 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
US8288440B2 (en) | 2005-05-20 | 2012-10-16 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
US20070197473A1 (en) * | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
US20070197568A1 (en) * | 2005-11-04 | 2007-08-23 | Paul Bunn | Methods of using SAHA and Erlotinib for treating cancer |
US20090247549A1 (en) * | 2005-11-04 | 2009-10-01 | Frankel Stanley R | Methods of using saha and bortezomib for treating cancer |
US9724321B2 (en) | 2006-02-14 | 2017-08-08 | President & Fellows Of Harvard College | Histone deacetylase inhibitors |
US10172821B2 (en) | 2006-02-14 | 2019-01-08 | President & Fellows of Harvard College Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors |
US9199923B2 (en) | 2006-02-14 | 2015-12-01 | President And Fellows Of Harvard College | Histone deacetylase inhibitors |
US20100113392A1 (en) * | 2006-11-03 | 2010-05-06 | Badros Ashraf Z | Methods of using saha and bortezomib for treating multiple myeloma |
US20100113602A1 (en) * | 2007-02-27 | 2010-05-06 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
US7994357B2 (en) | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
US20100256401A1 (en) * | 2009-04-03 | 2010-10-07 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
EP2236503A1 (en) | 2009-04-03 | 2010-10-06 | NatureWise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
EP2277387A1 (en) | 2009-07-22 | 2011-01-26 | NatureWise Biotech & Medicals Corporation | New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly |
WO2011056542A1 (en) | 2009-10-26 | 2011-05-12 | Ramot At Tel-Aviv University Ltd. | Cancer therapy with combinations of fts with hdac inhibitors |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
WO2012120262A1 (en) | 2011-03-09 | 2012-09-13 | Larsson Pia | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
WO2014018625A1 (en) | 2012-07-25 | 2014-01-30 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
EP3381943A1 (en) | 2012-07-25 | 2018-10-03 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US9650379B2 (en) | 2013-12-12 | 2017-05-16 | Chong Kun Dang Pharmaceutical Corp. | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same |
US11420950B2 (en) | 2015-05-22 | 2022-08-23 | Chong Kun Dang Pharmaceutical Corp. | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE38506E1 (en) | Potent inducers of terminal differentiation and methods of use thereof | |
US5369108A (en) | Potent inducers of terminal differentiation and methods of use thereof | |
US5700811A (en) | Potent inducers of terminal differentiation and method of use thereof | |
US5055608A (en) | Novel potent inducers of thermal differentiation and method of use thereof | |
US5840960A (en) | Potent inducers of terminal differentiation and method of use thereof | |
US5175191A (en) | Potent inducers of terminal differentiation and methods of use thereof | |
US6511990B1 (en) | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | |
Marks et al. | Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential. | |
EP0594577B1 (en) | Novel potent inducers of terminal differentiation and method of use thereof | |
WO1991000257A1 (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
AU708115B2 (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
EP0564499B1 (en) | Novel amines, process for producing them and medicaments containing said compounds | |
CA2574103A1 (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
WO1990009092A2 (en) | Novel potent inducers of terminal differentiation and method of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 12 |
|
CC | Certificate of correction | ||
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: ZOLINZA (VORINOSTAT, SUBEROYLANILIDE HYDROXAMIC ACID); REQUESTED FOR 1433 DAYS Filing date: 20061202 Expiry date: 20111129 |
|
PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: ZOLINZA (VORINOSTAT, SUBEROYLANILIDE HYDROXAMIC ACID) Filing date: 20061202 Expiry date: 20111129 |